TW201402082A - Absorbent article - Google Patents

Abstract

Provided is an absorbent article that is capable of preventing detachment of a sheet that constitutes a wing section, said detachment resulting from a composition that is applied to a top sheet penetrating the wing section when said wing section has been folded and bent. A protruding section is provided to the top sheet of the absorbent article of the present invention in an excretory orifice contact region that is at least in contact with the excretory orifice of a wearer on the skin-side surface of said contact region. The top sheet is additionally provided with a composition application region to which a predetermined composition is applied at least in the region that is in contact with the excretory orifice of the wearer.

Description

Absorbent article

The present invention relates to absorbent articles for sanitary napkins, pads, incontinence pads, incontinence pads and the like.

An absorbent article which is known in the prior art to provide a skin care composition to a skin sheet of a main body portion (for example, Patent Document 1). On the surface sheet of the absorbent article, an apertured formed film is used. Further, a flap formed by extending the surface sheet in the width direction is provided on the absorbent article.

[prior technical literature] [Patent Document]

[Patent Document 1] Japanese Patent Publication No. 2003-510164

As described in Patent Document 1, when the wrinkle of the absorbent article is to be folded, the skin of the surface sheet of the main body portion is present. The maintenance composition is impregnated into the wings by folding the opening portion of the surface sheet in the wing portion. At this time, by adhering the skin care composition, the bonding force between the surface sheet and the back sheet in the wing portion is weakened, and when the absorbent article is used for a long period of time, the surface sheet is peeled off from the back sheet.

The present invention provides an object of preventing an absorbent article which is formed by peeling a composition of a surface sheet from the wing portion and peeling off a sheet constituting the wing portion when the wing portion is folded.

In order to solve the above problems, the present invention adopts the following configuration.

In other words, the absorbent article of the present invention has a pair of wing portions having a main body portion and two side edges extending from the main body portion in the width direction, and the main body portion is provided with liquid permeability provided on the skin side. a non-woven surface sheet, a liquid-impermeable back sheet provided on the garment side, and an absorbent article provided on the liquid-retaining absorbent body between the surface sheet and the back sheet, the surface sheet being at least the wearer's side on the skin side The excretory opening engaging region of the excretory opening is provided with a protrusion, and the surface layer is further provided with a composition coating region for coating the predetermined composition on at least the excretory opening interface.

The absorbent article of the present invention has a pair of wing portions extending in the width direction from the main body portion and both side edges of the main body portion in the longitudinal direction and the width direction, and the main body portion is provided with liquid permeability provided on the skin side. The non-woven surface sheet, the liquid-impermeable back sheet provided on the garment side, and the absorbent article of the liquid-retaining absorbent body provided between the surface sheet and the back sheet, from the surface sheet to the inside of the absorber Formed by embossing The compression unit includes a drain port engagement region that is connected to at least the wearer's drain opening on the side of the skin, and the surface layer sheet is a composition application region that is coated with the predetermined composition at least in the drain port engagement region.

In the present invention, when the folded wing portion is restrained, the composition which is applied to the surface layer sheet penetrates the wing portion to peel off the sheet constituting the wing portion.

1,1D, 1E‧‧‧Absorbables

2,2A~2D‧‧‧Skin sheet

3‧‧‧Back sheet

4,4D‧‧‧ absorber

5,5E‧‧‧ side layer

6‧‧‧Wings

7‧‧‧Adhesive

8‧‧‧ Pressing ditch

8D‧‧‧Compression Department

9‧‧‧ Sealing Department

10‧‧‧ Body Department

16‧‧‧Excretion junction area

18‧‧‧ Blood Modifier Coating Area

21, 21A~C, 51E‧‧‧ protrusion

22,22A~22C‧‧‧ recess

26A, 26C‧‧‧ openings

120‧‧‧Network

121‧‧‧ protrusion

122‧‧‧ditch

130‧‧‧ mesh support member

140‧‧‧Blowing out

150‧‧‧Attraction

160‧‧‧Slim components

Fig. 1 is a partially cutaway plan view showing an embodiment of an absorbent article of the present invention.

Fig. 2 is a schematic cross-sectional view showing a cross section taken along line A-A of Fig. 1.

[Fig. 3] Fig. 3 is a view showing a projection and a concave portion of a surface sheet in an absorbent article according to an embodiment of the present invention.

Fig. 4 is a view showing a method of forming a projection and a recess in a surface sheet.

[Fig. 5] Fig. 5 is a view showing an absorbent article according to an embodiment of the present invention in which a wing portion is folded at the time of packaging.

Fig. 6 is a perspective view showing a package containing an absorbent article according to an embodiment of the present invention.

Fig. 7 is a schematic cross-sectional view showing a cross section taken along line D-D of Fig. 5.

[Fig. 8] Fig. 8 is a view showing a projection, a concave portion, and an opening portion of a surface sheet in a modified example of the absorbent article according to the embodiment of the present invention.

[Fig. 9] Fig. 9 is a view showing a method of forming an opening in a modified example of the absorbent article according to the embodiment of the present invention.

[Fig. 10] Fig. 10 is a view showing a projection of a surface sheet in a modified example of the absorbent article according to the embodiment of the present invention.

[Fig. 11] Fig. 11 is a view showing a projection, a recess, and an opening of a surface sheet in a modified example of the absorbent article according to the embodiment of the present invention.

[ Fig. 12] Fig. 12 is a view showing a modification of the absorbent article according to the embodiment of the present invention.

[Fig. 13] Fig. 13 is a view showing a modification of the absorbent article according to the embodiment of the present invention.

Fig. 14 is an electron micrograph showing the skin contact surface of the surface sheet in the sanitary napkin containing the tri-C2L oil fatty acid glyceride.

Fig. 15 shows a micrograph of menstrual blood with or without a blood modifying agent.

Fig. 16 is a view showing a method of measuring surface tension.

Type of implementation of the invention

The invention will be described below with reference to the drawings, but the invention is not limited to the drawings.

Fig. 1 is a partially cutaway plan view showing an absorbent article according to an embodiment of the present invention, and Fig. 2 is a view showing a cross section taken along line A-A of Fig. 1. Sectional view. The absorbent article 1 is a liquid-permeable surface sheet 2 provided on the skin side (skin contact side), a liquid-impermeable back sheet 3 provided on the garment side (non-skin contact side), and a surface sheet 2 and The liquid retaining body 4 between the back sheets 3 and the body portion 10 of the liquid-impermeable side sheet layer 5 provided on both sides in the width direction of the top sheet 2 are provided on both sides of the body portion 10 One of the side panel layer 5 and the back sheet 3 extending in the direction is opposite to the wing portion 6.

Reference numeral 61 denotes a base portion of the wing portion 6 (a boundary between the body portion 10 and the wing portion 6). For example, in the longitudinal direction of the wing portion 6, the straight line connecting the two points where the width of the absorbent article 1 is rapidly increased is the base 61 of the wing portion 6. An adhesive portion 7 is provided on the side of the garment on the wing portion 6. Further, an adhesive portion 7 is also provided on the side surface of the body of the main body portion 10. Further, in Fig. 1, the width direction of the absorbent article 1 is the X direction, and the long direction is the Y direction. Moreover, the planar direction of the absorbent article 1 is an XY direction. Further, the side sheet layer 5 may not be provided, and the surface sheet 2 of the main body portion 10 may be extended in the width direction, so that the wing portion 6 is provided with the surface sheet 2 and the back sheet 3.

The shape of the main body portion 10 is a rectangular shape, an elliptical shape, a sand time meter type or the like, and is not particularly limited as long as it is suitable only for the shape of the shape of the female body and the underwear. The extension in the longitudinal direction of the outer shape of the body portion 10 is preferably from 100 to 500 mm, more preferably from 150 to 350 mm. Further, the extension in the width direction of the outer shape of the main body portion 10 is preferably 30 to 200 mm, more preferably 40 to 180 mm.

The top sheet 2 is urine, menstrual blood, etc. discharged from the wearer The body fluid moves to the absorber 4. All or a part of the surface sheet 2 is liquid permeable, and the liquid permeation area of the surface sheet 2 is formed by a liquid permeable non-woven fabric, a woven fabric, a resin film formed by a plurality of liquid permeation holes, or a mesh sheet having a plurality of meshes. .

The top sheet 2 is preferably made of a non-woven fabric. As the raw material of the nonwoven fabric used for the surface sheet 2, any of natural fibers and chemical fibers can be used. Examples of the natural fiber include cellulose such as fluff pulp or cotton. Examples of the chemical fiber include regenerated cellulose such as rayon and fibril rayon, semi-synthetic cellulose such as acetate and triacetate, thermoplastic hydrophobic chemical fiber, and thermoplastic hydrophobic treated with hydrophilization treatment. Chemical fiber. Examples of the thermoplastic hydrophobic chemical fiber include a single fiber such as polyethylene (PE), polypropylene (PP), or polyethylene terephthalate (PET), and a fiber obtained by graft-polymerizing PE and PP. Composite fiber such as core sheath structure.

When the non-woven fabric used for the surface sheet 2 is produced, any of a dry method (a card method, a spunbond method, a melt blow method, an air laid method, or the like) and a wet method may be used, and a combined dry method and a wet method may be implemented. The web of law is formed. Examples of the bonding method of the network for producing the non-woven fabric for the surface sheet 2 include thermal bonding, needle punching, chemical bonding, and the like, but are not limited to these methods. Further, a spunlace formed into a sheet by a water flow entanglement method can be used for the surface sheet 2.

In the non-woven fabric of the surface sheet 2, a core-sheath type in which the melting point of the core component is higher than the sheath component, an eccentric type of the core sheath, or a side-by-side type composite fiber in which the melting points of the left and right components are different can be used. Also, Split fibers of hollow type fibers, or flat fibers, Y-type and C-type fibers, or three-dimensional crimped fibers that are sometimes crimped or crimped, or physical loads such as water flow, heat or embossing The fibers are mixed with the non-woven fabric used for the surface sheet 2.

The fiber used for the non-woven fabric of the surface sheet 2 is preferably 1.1 to 8.8 dtex in consideration of the suction of the liquid and the touch of the skin.

When the hydrophobic synthetic fiber is used for the surface sheet 2, a hydrophilic agent or a water repellent agent may be mixed with the hydrophobic synthetic fiber in consideration of liquid absorption or rewetting property of the surface sheet 2, or a hydrophilic agent or water may be used. The agent or the like is applied to the hydrophobic synthetic fiber. Further, the hydrophobic synthetic fiber may be rendered hydrophilic by corona treatment or plasma treatment. Therefore, when the blood modifying agent described later is lipophilic, in the blood modifying agent application region 18, the hydrophilic portion and the lipophilic portion will coexist sparsely, and the hydrophilic component (mainly plasma) of the body fluid (for example, menstrual blood) and the pro- Both of the oily components (mainly blood cells) are quickly moved from the surface sheet 2 to the absorber 4.

In order to increase the opacity of the surface sheet 2, the nonwoven fabric used for the non-woven fabric of the surface sheet 2 may contain an inorganic filler such as titanium oxide, barium sulfate or calcium carbonate. When the non-woven fabric is a core-sheath type composite fiber, the inorganic filler may be contained only in the core, or may be contained only in the sheath.

At least the excretion port engagement region 16 of the surface sheet 2 is provided with a blood modifying agent application region 18 coated with a blood modifying agent to be described later. Here, the excretory opening engagement region 16 is a length in the longitudinal direction of the center of the excretory opening contacting the wearer's body fluid, preferably 50 to 200 mm, more preferably 70 to 150 mm, and the length in the width direction is preferably 10 ~80mm, better It is 20~50mm. When the absorbent article 1 is to be wrapped, when the wide outer side edges 62 of the pair of wing portions 6 are engaged with each other and the pair of wing portions 6 are folded inward in the width direction, most or all of the blood modifying agent application region 18 is caused by The folded wing portion 6 is covered and hidden (see Figs. 5 and 7).

The top sheet 2 is at least the excretory opening engagement region 16, and has a projection 21 and a recess 22 which extend in the longitudinal direction (Y direction) and intersect in the longitudinal direction (Y direction), for example, in the width direction (X direction). . The projection 21 and the recess 22 provided in the surface sheet 2 will be described in detail with reference to Fig. 3 . 3 is an enlarged perspective view showing the projection 21 and the recess 22 of the top sheet 2. Further, the direction in which the protrusion 21 and the recess 22 extend is only a predetermined direction, and is not limited to the long direction.

As shown in FIG. 3, the surface sheet 2 extends in the longitudinal direction (Y direction) and includes a plurality of protrusions 21 and recesses 22 which are arranged in the longitudinal direction (Y direction), for example, in the width direction (X direction). The cross-sectional shape of the protrusion 21 has, for example, a slightly U-shape. In addition to the U-shape, the U-shaped shape also includes a U-shape in which the angle is rounded and the straight line is curved or the like. For example, the U-shape includes a V-shape, an M-shape, and a trapezoid. Further, the cross-sectional shape of the protrusion 21 may be an Ω shape.

The thickness of the thicker portion of the projection 21 is preferably from 0.3 to 15 mm, more preferably from 0.5 to 5 mm. Further, the length in the width direction (X direction) of the projection is preferably 0.5 to 30 mm, more preferably 1.0 to 10 mm. The distance (pitch) between the apexes of the width direction (X direction) of the adjacent protrusions is preferably 0.5 to 30 mm, more preferably 3 to 10 mm. a thinner portion of the recess 22 The thickness of the thicker portion of the protrusion 21 is preferably from 1 to 50%, more preferably from 5 to 20%. The length of the concave portion 22 in the width direction (X direction) is preferably 0.1 to 30 mm, more preferably 0.5 to 10 mm.

The fiber density of the central portion 23 of the projection 21 is preferably lower than the fiber density of the side portion 24 and/or the recess 22 of the projection 21. For example, the central portion 23 and the concave portion 22 of the projection 21 have a fiber density of 0.005 to 0.20 g/cm ³ , preferably 0.007 to 0.07 g/cm ³ . The fiber density of each place of the surface sheet can be measured, for example, as shown below. A surface sheet forming the length of the predetermined mechanical direction (MD) of the projection 21 and the recess 22 is sampled. Then, using a microscope or the like, a cross-sectional micrograph of the width direction (CD) of the surface sheet is photographed, and the cross-sectional area of the central portion of the protrusion 21 of the surface sheet, the cross-sectional area of the side portion of the projection, and the cross-sectional area of the concave portion are used. The processing device performs the measurement. Next, the surface sheet is cooled by liquid nitrogen or the like, and the central portion of the projection of the cooled surface sheet, the side portion of the projection, and the concave portion are separated from each other. However, the weight of the central portion of the excised projection, the side portion of the projection, and the recess were measured. Finally, by dividing the weight measured in the central portion of the projection, the side portion of the projection, and the recessed portion by the length and cross-sectional area of the machine direction (MD), the fiber density at the central portion of the projection of the surface sheet can be calculated. The fiber density at the side of the portion and the fiber density of the recess. Further, the relationship between the fiber density of the central portion 23 of the projection 21 and the fiber density of the side portion 24 of the projection 21 and/or the concave portion 22 is determined by the density relationship of the fibers of the cross-sectional micrograph of the surface sheet. . The symbol 25 of the fiber density indicates the fiber of the top sheet 2.

Next, referring to FIG. 4, the formation of the protrusions in the surface sheet 2 will be described. 21 and the method of the recess 22. As shown in FIG. 4, the network 120 which is the material of the surface sheet 2 is placed on the mesh supporting member 130, and then moved in the machine direction (MD). The network 120 moves between the blowing portion 140 and the suction portion 150. The blowing unit 140 sprays the gas 141 on the network 120, and the suction unit 150 sucks the gas 141 injected from the blowing unit 140. The gas 141 ejected from the blowing portion 140 disengages the fibers of the network 120. Thereby, the groove 122 corresponding to the concave portion 22 of the surface sheet 2 is formed on the network 120. Further, the fibers which are separated by the gas 141 ejected from the blowing portion 140 are concentrated on both sides of the groove 122. Thereby, the protrusions 121 corresponding to the protrusions 21 of the surface sheet 2 are formed on both sides of the groove 122.

The mesh supporting member 130 is a permeable mesh support. For example, a resin yarn such as polyester, polyphenylene sulfide, nylon or conductive monofilament, or a metallic yarn such as stainless steel, copper or aluminum can be used, such as plain weave, twill weave, satin weave, double weave, and spiral. A woven mesh which is woven or the like is used as the mesh supporting member 130.

The blowing portion 140 includes a plurality of air outlets (not shown) that are arranged side by side in the width direction. Thereby, the blowing portion 140 can eject the plurality of gases 141 side by side in the width direction (CD) to the network 120. Further, the gas 141 ejected from the blowing portion 140 may be, for example, normal temperature or heated nitrogen gas, air, or water vapor. The gas 141 ejected from the blowing portion 140 may contain liquid or solid particles.

By making the blowing portion 140 reciprocate in the width direction (CD), a serpentine (corrugated, zigzag) groove portion can be formed on the network. Further, the gas 141 is intermittently ejected from the blowing portion 140 to the network 120. After that, a discontinuous groove can be formed on the network.

The side of the protrusion 121 is densely plucked by the fibers, so that the side of the protrusion 121 has a high fiber density. Further, the groove 122 is in the forward direction of the gas 141 ejected from the blowing portion 140, and the network thereof is compressed, so that the fiber density in the groove 122 is increased. On the other hand, in the central portion of the projection 121, even if the fibers that have been plucked are concentrated, they are not compressed by the gas 141 ejected from the blowing portion 140, so that the fiber density at the central portion of the projection 121 is lowered. Thereby, the fiber density of the central portion 23 of the projection 21 is lower than the fiber density of the side portion 24 and/or the recess 22 of the projection 21.

The back sheet 3 shown in Figs. 1 and 2 prevents the body fluid absorbed by the absorber 4 from leaking out. For the back sheet 3, a material that does not penetrate the body fluid is used. For example, as the back sheet 3, a water-repellent non-woven fabric, a water-impermeable plastic film such as polyethylene or polypropylene, or a laminated sheet of a non-woven fabric and a water-impermeable plastic film is used. Further, the melt-blown nonwoven fabric having high water resistance is spunbonded by a spunbonded nonwoven fabric having a strong strength, and the sawtooth meltblown/spunbond (SMS) fiber nonwoven fabric can also be used as the backsheet 3. When a material having a gas permeability that does not pass through a body fluid is used as the back sheet 3, leakage at the time of wearing can be reduced. The back sheet 3 is joined to the topsheet 2 by using an adhesive such as a hot melt adhesive.

The absorber 4 is held after absorbing body fluid. The absorbent body 4 is high in volume, and the outer shape is not easily broken, and it is preferable that less chemical irritant is used. For example, as the absorbent body 4, a composite absorbent body formed of fluffy pulp or air-laid nonwoven fabric and a highly absorbent polymer (SAP) can be used. The composite absorbent body may be covered with a liquid permeable material such as toilet paper.

Further, in place of the fluffy pulp of the composite absorbent body, for example, artificial cellulose fibers such as chemical pulp, cellulose fibers, rayon, and acetate can be used. The basis weight of the absorbent fiber such as pulp in the composite absorbent body is preferably 100 g/m ² or more and 800 g/m ² or less, and the mass ratio of the superabsorbent polymer in the composite absorbent body is such that the absorbent fiber is used as the absorbent fiber. When it is 100%, it is preferably 10% or more and 65% or less. The basis weight of the liquid permeable material such as toilet paper covering the composite mixture is preferably 12 g/m ² or more and 30 g/m ² or less.

As the air-laid nonwoven fabric of the above composite composite, for example, a non-woven fabric in which a pulp and a synthetic fiber are thermally fused, or a non-woven fabric in which a pulp and a synthetic fiber are fixed by a binder can be used.

The superabsorbent polymer of the above composite absorbent is a three-dimensional mesh structure having a water-soluble polymer which is moderately crosslinked. The absorbent polymer absorbs 30 to 60 times of water for the volume of the absorbent polymer before absorbing water. However, the absorbent polymer is inherently water insoluble. Further, even if the pressure is applied to the absorbent polymer, it is not separated from the water once absorbed. As the absorbent polymer, for example, a starch-based, acrylic or amino acid-based particulate or fibrous polymer can be used.

The shape and structure of the absorbent body 4 may be changed as necessary, but the total absorption amount of the absorbent body 4 must correspond to the design insertion amount and the intended use of the absorbent article 1. Further, the size, absorption capacity, and the like of the absorbent body 4 can be changed in accordance with the use.

The absorbent body 4 using the hot melt adhesive is followed by the surface sheet 2. Thereby, peeling of the surface sheet 2 from the absorber 4 can be suppressed.

The side panel layer 5 prevents the body fluid from passing through the surface and/or the inside of the surface sheet 2 and leaks outside the outer side in the width direction of the absorbent article 1. The side panel layer 5 is preferably one having hydrophobicity or water repellency. As the side sheet layer 5, for example, a spunbonded nonwoven fabric or an SMS non-woven fabric or the like is used. Further, since the side panel layer 5 is in contact with the skin of the wearer, it is preferable to use a breathable nonwoven fabric which can reduce the frictional stimulation to the skin as the side panel layer 5. Also, the absorbent article 1 may not have the side panel layer 5.

As described above, the wing portion 6 is provided in the absorbent article 1 in order to stably fix the absorbent article 1 to the underwear. After the wing portion 6 is folded over the outer side of the underwear, the adhesive portion 7 is attached to the crotch region of the underwear, and the absorbent article 1 can be stably fixed to the underwear. Further, when the adhesive portion 7 provided on the main body portion 10 is attached to the underwear crotch region, the displacement of the main body portion 10 can be suppressed during wearing.

As shown in Fig. 2, the adhesive portion 7 of the absorbent article 1 is such that the absorbent article 1 is fixed to the crotch region of the underwear. As the adhesive for forming the adhesive portion 7, for example, any one of a polyethylene-based polymer, an adhesive-imparting agent, and a plasticizer can be used as a main component. Examples of the styrene-based polymer include a styrene-ethylene-butylene-styrene block copolymer, a styrene-butene copolymer, a styrene-butene-styrene block copolymer, and styrene- The isobutylene-styrene copolymer or the like may be used alone or in combination of two or more kinds of polymers. Among them, a styrene-ethylene-butylene-styrene block copolymer is preferred from the viewpoint of good thermal stability.

In addition, as the adhesion-imparting agent and the plasticizer, it is preferred to use a solid at room temperature, and an adhesive-imparting agent, for example, C5-based petroleum Resin, C9-based petroleum resin, dicyclopentadiene-based petroleum resin, rosin-based petroleum resin, polydecene resin, terpene phenol resin, etc., and examples of the plasticizer include tricresyl phosphate and dibutyl phthalate. In addition to the monomeric plasticizer such as ester or dioctyl phthalate, a polymer plasticizer such as an ethylene polymer or a polyester may also be mentioned.

As shown in FIGS. 1 and 2, the surface sheet 2 and the absorber 4 are formed by compression in the thickness direction by embossing, and have a press groove 8 from the surface sheet 2 to the inside of the absorber 4. The squeezing groove 8 is formed so as to be diffused in the width direction (X direction) by the body fluid discharged from the central portion of the absorbent article 1 (the portion where the body fluid discharge port of the wearer contacts). Further, by this, peeling of the surface sheet 2 of the self-absorbent body 4 can be suppressed. The squeezing groove 8 is a central portion surrounding the absorbent article 1, and has a shape of a continuous substantially annular shape. Further, the press groove 8 surrounding the central portion of the absorbent article 1 can be partially interrupted. That is, the press groove 8 has a shape that can have a discontinuous slightly annular shape.

Further, after the surface sheet 2 is compression-bonded to the back sheet 3 by hot embossing, the sealing portion 9 is formed on both the edge portions in the longitudinal direction of the main body portion 10 and the outer side edge portion in the width direction of the wing portion 6. Thereby, peeling of the surface sheet 2 from the back sheet 3 can be avoided. Further, the back sheet 3 and the side sheet layer 5 are joined by the sealing portion 9 of the wing portion 6 by hot embossing. Thereby, peeling of the side panel layer 5 from the back sheet 3 can be avoided.

Next, the above blood modifying agent will be described in detail. The blood modifying agent has a melting point of from about 0.00 to about 0.60 IOB and a melting point of about 45 ° C or less, and a water solubility of from about 0.00 to about 0.00 to about 0.05 g to 100 g of water at 25 ° C.

IOB (Inorganic Organic Balance) is an index indicating the balance between hydrophilicity and lipophilicity. In this specification, the values calculated by Oda by the following formula are shown: IOB = inorganic value / organic value

The above-mentioned inorganic value and organic value are based on the organic concept map described in Fujita Mu's "Predicting and Organic Concepts of Organic Compounds", Vol. 11, No. 10 (1957) p. 719-725. Fujita's summary of the organic and inorganic values of the main groups is summarized in Table 1 below.

For example, in the case of an ester of a tetradecanoic acid having a carbon number of 14 and a dodecyl alcohol having a carbon number of 12, the organic value is 520 (CH ₂ , 20 × 26), and the inorganic value is 60 (- When COOR, 60 × 1), IOB = 0.12.

The above blood modifying agent has an IOB of from about 0.00 to about 0.60, preferably from about 0.00 to about 0.50, more preferably from about 0.00 to about 0.40, most preferably from about 0 to about 0.30. The lower the IOB, the higher the organicity and the higher the affinity with the blood cells.

In the present specification, the "melting point" is the peak top temperature of the endothermic peak when changing from a solid state to a liquid state when measured at a temperature increase rate of 10 ° C /min in a differential scanning calorimeter. The melting point is measured by, for example, a DSC-60 DSC measuring apparatus manufactured by Shimadzu Corporation.

The above blood modifying agent has a melting point of about 45 ° C or less, and may be a liquid even at room temperature, or may be a solid, even if the melting point is above about 25 ° C, or may be less than about 25 ° C, for example, may have - 5 ° C, a melting point of about -20 ° C. The basis of the above-mentioned blood modifying agent having a melting point of about 45 ° C or less is as follows.

Although the melting point of the above blood modifying agent does not have a lower limit, the lower the vapor pressure, the better. The vapor pressure of the blood modifying agent is preferably from about 0.00 to about 0.01 Pa at 1 atm and 25 ° C, preferably from about 0.000 to about 0.001 Pa, more preferably from about 0.0000 to about 0.0001 Pa. When the absorbent article disclosed in the present invention is used in contact with a human body, the vapor pressure is preferably from about 0.00 to about 0.01 Pa at 1 atm and 40 ° C, preferably from about 0.000 to about 0.001 Pa, and about 0.0000 °. Approximately 0.0001 Pa is preferred. If the vapor pressure is high, it will vaporize during storage, and sometimes the amount of blood modifying agent will decrease. Less, the stench of wearing and so on.

Moreover, the melting point of the blood modifying agent can be distinguished by the climate, the length of the wearing time, and the like. For example, when a blood modifying agent having a melting point of about 10 ° C or lower is used in an area having an average temperature of about 10 ° C or less, the blood modifying agent can stably reform the blood even if it is cooled by the ambient temperature after excretion by blood. Further, when the absorbent article is used for a long period of time, the melting point of the blood modifying agent is preferably in a higher range of 45 ° C or lower. It is not easy to be affected by the friction during wearing, and it is not easy to move the blood modifying agent even if it is worn for a long time.

The solubility of water of 0.00~0.05g is 25 °C, and after adding 0.05g of sample to 100g of deionized water, it is allowed to stand for 24 hours. After 24 hours, gently stir as necessary, and then visually evaluate whether the sample is dissolved. The measurement was carried out. Further, in the present specification, regarding the water solubility, "dissolution" includes a case where the sample is completely dissolved in the deionized water, a case where a homogeneous mixture is formed, and a case where the sample is completely emulsified. The so-called "complete" means that there is no sample block in the deionized water.

In this technical field, the surface of the surface sheet is coated with a surfactant as a purpose of changing the surface tension of blood or the like to rapidly absorb the blood. However, the surfactant generally has a high water solubility, so that the surface layer of the surfactant is highly compatible with the hydrophilic component (plasma, etc.) in the menstrual blood, and the tendency to retain the menstrual blood on the surface sheet. . Since the blood modifying agent has a low water solubility, it is different from the conventionally known surfactant, and the menstrual blood does not remain on the surface sheet, and can be quickly moved to the absorber.

The solubility in 100 g of water at 25 ° C in this specification is simply referred to as "water solubility".

In the present specification, the "weight average molecular weight" is a compound containing a polydisperse system (for example, a compound produced by sequential polymerization, an ester of a complex fatty acid and a plurality of aliphatic monohydric alcohols) and a single compound (for example, one type) The concept of an ester produced by a fatty acid and one aliphatic monohydric alcohol) is expressed by the following molecules (i=1, or i=1, 2‧‧‧) composed of N _i molecular weights M _i Formula: M _w =Σ N _i M _i ² /Σ N _i M _i

The Mw obtained.

In the present specification, the weight average molecular weight means a polystyrene-converted value obtained by gel permeation chromatography (GPC). Examples of the measurement conditions of the GPC include the following.

Model: (shares) Hitachi high-tech high-speed liquid chromatography Lachrom Elite

Pipe column: SHODEX KF-801, KF-803 and KF-804 made by Showa Denko Electric Co., Ltd.

Dissolution: THF

Flow rate: 1.0mL/min

Driving amount: 100μL

Detection: RI (differential refractometer)

Further, the weight average molecular weight described in the examples of the present specification is measured by the above conditions.

Preferably, the blood modifying agent is selected from the following (i)~ (iii), (i) a hydrocarbon, (ii) having a (ii-1) hydrocarbon moiety and (ii-2) interposed between the CC single bond of the hydrocarbon moiety selected from the group consisting of a carbonyl group (-CO-) and an oxy group (- O-) a group of one or more identical or different groups of compounds, and (iii) having a (iii-1) hydrocarbon moiety, (iii-2) interposed between the CC single bonds of the hydrocarbon moiety One or more identical or different groups grouped from a carbonyl group (-CO-) and an oxy group (-O-) and (iii-3) a hydrogen atom substituted for the above hydrocarbon moiety selected from a carboxyl group (-COOH) And a compound in which one or more of the same or different groups of the hydroxyl group (-OH) are grouped, and any combination thereof.

For the purposes of this specification, a "hydrocarbon" in a hydrocarbon moiety means a compound formed from a carbon number and hydrogen, a chain hydrocarbon such as a paraffinic hydrocarbon (which does not contain a double bond or a bond, also referred to as an alkane), or an olefinic hydrocarbon (containing 1 Double bonds, also known as alkenes), acetylene hydrocarbons (containing one ginseng, also known as alkyne), and two or more hydrocarbons selected from the group consisting of double bonds and bond bonds, and cyclic The hydrocarbon contains, for example, an aromatic hydrocarbon or an alicyclic hydrocarbon.

The hydrocarbon is preferably a chain hydrocarbon or an alicyclic hydrocarbon, preferably a chain hydrocarbon, and a paraffinic hydrocarbon, an olefin hydrocarbon, and a hydrocarbon having two or more double bonds (without a bond). Good, and paraffinic hydrocarbons are particularly good. The chain hydrocarbon contains a linear hydrocarbon and a branched hydrocarbon.

In the case of the above compounds (ii) and (iii), when two or more oxy groups (-O-) are inserted, each oxy group (-O-) is not adjacent. Therefore, the compounds of the above (ii) and (iii) do not contain an oxy group in a continuous manner. Compound (so-called peroxide).

Further, in the compound of the above (iii), a compound in which at least one hydrogen atom of the hydrocarbon moiety is substituted by a carboxyl group (-COOH), and a compound in which at least one hydrogen atom of the hydrocarbon moiety is substituted by a hydroxyl group (-OH) is a compound. good. As shown in Table 1, the carboxyl group is combined with the metal in the menstrual blood, and the inorganic value is greatly improved from 150 to 400 or more. Therefore, the blood modifying agent having a carboxyl group sometimes increases the value of the IOB to about 0.60, the affinity with blood cells may be reduced.

Preferably, the blood modifying agent is selected from the group consisting of (i') to (iii') and any combination thereof, (i') hydrocarbon, (ii') having (ii'-1) hydrocarbon moiety and ( Ii'-2) a carbonyl bond (-CO-), an ester bond (-COO-), a carbonate bond (-OCOO-), and an ether bond (-O-) interposed between the CC single bonds of the above hydrocarbon moiety. a choice of one or a plurality of identical or distinctly bonded compounds, and (iii') (iii'-1) hydrocarbon moiety, (iii'-2) inserted between the CC single bonds of the hydrocarbon moiety One or a plurality of identical or distinct bonds from a carbonyl bond (-CO-), an ester bond (-COO-), a carbonate bond (-OCOO-), and an ether bond (-O-) Iii'-3) A compound which replaces one or more of the same or different groups of the hydrogen atom of the above hydrocarbon moiety selected from the group consisting of a carboxyl group (-COOH) and a hydroxyl group (-OH).

In the above compounds (ii') and (iii'), when two or more identical or different bonds are inserted, the insertion is selected from a carbonyl bond (-CO-), an ester bond (-COO-), and a carbonate bond ( -OCOO-) and ether bond (-O-) 2 When more than one of the same or different bonds are bonded, the bonds are not adjacent, and at least one carbon number atom is interposed between the bonds.

More preferably, the above-mentioned blood modifying agent has a carbonyl bond (-CO-) of about 1.8 or less per 10 carbon atoms in the hydrocarbon moiety, and an ester bond (-COO-) of 2 or less, and a carbonate bond (- OCOO-) is a compound having about 1.5 or less, an ether bond (-O-) of about 6 or less, a carboxyl group (-COOH) of about 0.8 or less, and/or a hydroxyl group (-OH) of about 1.2 or less.

Preferably, the blood modifying agent is selected from the group consisting of (A) to (F) and any combination thereof; (A) (A1) having a chain hydrocarbon portion and a hydrogen atom replacing the chain hydrocarbon portion; a compound having 2 to 4 hydroxyl groups and (A2) an ester having a chain hydrocarbon moiety and a compound which substitutes a carboxyl group of a hydrogen atom of the above-mentioned chain hydrocarbon moiety, and (B) (B1) having a chain hydrocarbon moiety and replacing the above chain a compound having 2 to 4 hydroxyl groups of a hydrogen atom of a hydrocarbon portion and (B2) an ether having a chain hydrocarbon moiety and a hydroxyl group replacing a hydrogen atom of the above-mentioned chain hydrocarbon moiety, and (C) (C1) a chain a hydrocarbon moiety, a carboxylic acid, a hydroxy acid, an alkoxy acid or a carbonyl acid which replaces 2 to 4 carboxyl groups of a hydrogen atom of the above-mentioned chain hydrocarbon moiety, and (C2) has a chain hydrocarbon moiety and a substituted chain hydrocarbon moiety An ester of a hydroxyl group compound of a hydrogen atom, (D) having a chain hydrocarbon moiety and a CC bond inserted in the chain hydrocarbon moiety selected from an ether bond (-O-) or a carbonyl bond (-CO-) a compound in which one of the ester bond (-COO-) and the carbonate bond (-OCOO-) is bonded, (E) a polyoxy C ₂ -C ₆ alkanediol or an alkyl ester thereof or an alkane a base ether, and (F) a chain hydrocarbon.

The blood modifying agent will be described in detail below based on (A) to (F).

[(A) (A1) has a chain hydrocarbon moiety and a compound of 2 to 4 hydroxyl groups which replaces the hydrogen atom of the above-mentioned chain hydrocarbon moiety, and (A2) has a chain hydrocarbon moiety and a hydrogen atom which substitutes the above-mentioned chain hydrocarbon moiety. Ester of a compound of a carboxyl group]

(A) (A1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups which replace the hydrogen atom of the above-mentioned chain hydrocarbon moiety, and (A2) having a chain hydrocarbon moiety and a hydrogen atom replacing the above chain hydrocarbon moiety The ester of a compound of a carboxyl group (hereinafter sometimes referred to as "compound (A)") may have only the above IOB, melting point and water solubility, and all of the hydroxyl groups may not be esterified.

(A1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups which replace the hydrogen atom of the chain hydrocarbon moiety (hereinafter sometimes referred to as "compound (A1)"), for example, a chain hydrocarbon tetraol For example, an alkane tetraol may be mentioned, for example, a pentaerythritol or a chain hydrocarbon triol, and examples thereof include an alkane triol, and examples thereof include glycerin and a chain hydrocarbon diol, and examples thereof include an alkane diol. For example, glycol can be mentioned.

(A2) a compound having a chain hydrocarbon moiety and a carboxyl group which replaces the hydrogen atom of the chain hydrocarbon moiety (hereinafter sometimes referred to as "compound (A2)"), for example, one hydrogen atom on a hydrocarbon The compound substituted with one carboxyl group (-COOH) may, for example, be a fatty acid.

Examples of the compound (A) include (a ₁ ) an ester of a chain hydrocarbon tetraol with at least one fatty acid, (a ₂ ) an ester of a chain hydrocarbon triol with at least one fatty acid, and (a ₃ ) a chain. An ester of a hydrocarbon diol with at least one fatty acid.

[(a1) ester of chain hydrocarbon tetraol with at least one fatty acid]

Examples of the ester of the chain hydrocarbon tetraol and at least one fatty acid include the following formula (1): a tetraester of pentaerythritol and a fatty acid, the following formula (2): a pentaerythritol and a fatty acid triester, the following formula (3): a diester of pentaerythritol and a fatty acid, the following formula (4): a monoester of pentaerythritol and a fatty acid.

(wherein, R ¹ to R ^{4 are} each a chain hydrocarbon)

As the fatty acid (R ¹ COOH, R ² COOH, R ³ COOH, and R ⁴ COOH) constituting the ester of pentaerythritol and a fatty acid, the ester of pentaerythritol and a fatty acid may satisfy only the above-mentioned requirements of IOB, melting point, and water solubility, and Specific examples of the saturated fatty acid include, for example, a saturated fatty acid having C ₂ to C ₃₀ , and examples thereof include acetic acid (C ₂ ) (C ₂ represents a carbon number and corresponds to R ¹ C, R ² C, and R). ³ C or R ⁴ C carbon number, the same below), propionic acid (C ₃ ), butyric acid (C ₄ ) and isomers thereof, for example, 2-methylpropionic acid (C ₄ ), valeric acid (C ₅ ) and its isomers include, for example, 2-methylbutyric acid (C ₅ ), 2,2-dimethylpropionic acid (C ₅ ), caproic acid (C ₆ ), and heptanoic acid (C). ₇ ), octanoic acid (C ₈ ) and its isomers, for example, 2-ethylhexanoic acid (C ₈ ), decanoic acid (C ₉ ), citric acid (C ₁₀ ), dodecanoic acid (C ₁₂ ), myristic acid (C ₁₄ ), palmitic acid (C ₁₆ ), heptadecanoic acid (C ₁₇ ), octadecanoic acid (C ₁₈ ), eicosanoic acid (C ₂₀ ), twenty-two Alkanoic acid (C ₂₂ ), tetracosanoic acid (C ₂₄ ), dihexadecanoic acid (C ₂₆ ), octadecanoic acid (C ₂₈ ), triacontanic acid (C ₃₀ ), etc., and these Structure Except as described above).

The above fatty acid may also be an unsaturated fatty acid. Examples of the unsaturated fatty acid include C ₃ to C ₂₀ unsaturated fatty acids, and examples thereof include monounsaturated fatty acids, and examples thereof include crotonic acid (C ₄ ), myristic acid (C ₁₄ ), and palm oil. Acid (C ₁₆ ), oleic acid (C ₁₈ ), oleic acid (C ₁₈ ), octadecenoic acid (C ₁₈ ), oleic acid (C ₂₀ ), eicosenoic acid (C ₂₀ ), etc. Examples of the diunsaturated fatty acid include a linoleic acid (C ₁₈ ), an eicosadiene (C ₂₀ ), and the like, and a triunsaturated fatty acid, and examples thereof include linolenic acid, and examples thereof include α-linolenic acid (C). ₁₈ ) and γ-linolenic acid (C ₁₈ ), pinoleic acid (C ₁₈ ), and tung acid, and examples thereof include α-tungstic acid (C ₁₈ ), β-tungstic acid (C ₁₈ ), and metyric acid (C). ₂₀ ), dimono-γ-linolenic acid (C ₂₀ ), eicosatrienoic acid (C ₂₀ ), etc., tetra-unsaturated fatty acids, for example, octadecatetraenoic acid (C ₂₀ ), arachidene acid (C _20), arachidonic acid (C _20), penta unsaturated fatty acids such as eicosapentaenoic acid include eighteen (C _18), eicosapentaenoic acid (C _20), and the like These partial hydrogen additions.

When the ester of the pentaerythritol and the fatty acid is considered to be likely to be modified by oxidation or the like, an ester of pentaerythritol derived from a saturated fatty acid and a fatty acid, that is, an ester of pentaerythritol and a saturated fatty acid is preferred.

Further, as the ester of the pentaerythritol and the fatty acid, in order to reduce the IOB, and to improve the hydrophobicity, a diester, a triester or a tetraester is preferred, a triester or a tetraester is preferred, and a tetraester is preferred. .

In the tetraester of the pentaerythritol and the fatty acid, the carbon number of the fatty acid constituting the tetraester of the pentaerythritol and the fatty acid, that is, the carbon number of the R ¹ C, R ² C, R ³ C and R ⁴ C portions in the above formula (1) If the total is 15, the IOB is 0.60. Therefore, in the tetraester of the pentaerythritol and the fatty acid, when the total carbon number is about 15 or more, the IOB is a requirement of satisfying from about 0.00 to about 0.60.

Examples of the pentaerythritol and the fatty acid tetraester include pentaerythritol and hexanoic acid (C ₆ ), heptanoic acid (C ₇ ), and octanoic acid (C ₈ ), and examples thereof include 2-ethylhexanoic acid (C ₈ ). a tetraester of citric acid (C ₉ ), citric acid (C ₁₀ ) and/or dodecanoic acid (C ₁₂ ).

In the above-mentioned pentaerythritol and a fatty acid triester, the total number of carbon atoms of the fatty acid constituting the pentaerythritol and the fatty acid triester is a total of 19 carbon atoms in the R ¹ C, R ² C and R ³ C portions in the above formula (2). The IOB is 0.58. Therefore, when the total number of carbon atoms of the above-mentioned pentaerythritol and fatty acid triester is about 19 or more, the requirement of IOB of about 0.00 to about 0.60 is satisfied.

In the diester of the pentaerythritol and the fatty acid, the total number of carbon atoms of the fatty acid constituting the diester of pentaerythritol and the fatty acid is, in the above formula (3), when the total carbon number of the R ¹ C and R ² C moieties is 22, the IOB is 0.59. . Therefore, in the diester of the pentaerythritol and the fatty acid, when the total carbon number of the fatty acid is about 22 or more, the requirement of IOB of about 0.00 to about 0.60 is satisfied.

The monoester of the pentaerythritol and the fatty acid constitutes the fatty acid carbon number of the pentaerythritol and the monoester of the fatty acid, that is, in the above formula (4), when the carbon number of the R ¹ C moiety is 25, the IOB is 0.60. Therefore, in the monoester of the pentaerythritol and the fatty acid, when the carbon number of the fatty acid is about 25 or more, the requirement of IOB of about 0.00 to about 0.60 is satisfied. And in the above calculations, the effects of double bonds, reference keys, iso branches, and tert branches are not considered.

As a commercial product of the ester of the above-mentioned pentaerythritol and a fatty acid, a Unistar H-408BRS, H-2408BRS-22 (mixed product), etc. (The above is manufactured by Nippon Oil Co., Ltd.) can be mentioned.

[(a ₂ ) an ester of a chain hydrocarbon triol with at least one fatty acid]

Examples of the ester of the chain hydrocarbon triol and at least one fatty acid include the following formula (5): The triglyceride of glycerol and fatty acid, the following formula (6): The diester of glycerol and fatty acid, and the following formula (7): (wherein, R ⁵ to R ^{7 are} each a chain hydrocarbon) a monoester of glycerin and a fatty acid.

The fatty acid (R ⁵ COOH, R ⁶ COOH, and R ⁷ COOH) constituting the ester of the glycerin and the fatty acid, and the ester of the glycerin and the fatty acid only satisfy the requirements of the above IOB, the melting point, and the water solubility, and are not particularly limited, and for example, The fatty acids listed in "(a ₁ ) chain hydrocarbon tetraol and at least one fatty acid ester" are exemplified by saturated fatty acids and unsaturated fatty acids, and the possibility of denaturation by oxidation or the like is considered. It is preferred to use an ester of glycerin and a fatty acid derived from a saturated fatty acid, that is, an ester of glycerin and a saturated fatty acid.

Further, as the ester of the glycerin and the fatty acid, in order to reduce the IOB and to improve the hydrophobicity, a diester or a triester is preferred, and a triester is more preferred.

The above-mentioned triglyceride of glycerin and fatty acid is also called triglyceride, and examples thereof include a triester of glycerin and caprylic acid (C ₈ ), a triester of glycerin and capric acid (C ₁₀ ), and glycerin and dodecanoic acid (C _{12 ).} a triester, and a triester of glycerin with two or three fatty acids, and mixtures thereof.

Examples of the triglyceride of the glycerin and the two or more kinds of fatty acids include glycerin and octanoic acid (C ₈ ) and triester of citric acid (C ₁₀ ), glycerin, octanoic acid (C ₈ ), and citric acid (C ₁₀ ). Triester with dodecanoic acid (C ₁₂ ), glycerin and octanoic acid (C ₈ ), citric acid (C ₁₀ ), dodecanoic acid (C ₁₂ ), myristic acid (C ₁₄ ), palmitic acid (C ₁₆ ) and a triester of octadecanoic acid (C ₁₈ ).

The triglyceride of the glycerin and the fatty acid is preferably a total of carbon atoms of a fatty acid constituting a triester of glycerin and a fatty acid, and R ⁵ C, R ⁶ C and R ⁷ C in the formula (5). A part of the total carbon number is preferably about 40 or less.

Further, in the triglyceride of the glycerin and the fatty acid, the carbon number of the fatty acid constituting the triester of glycerin and the fatty acid is total, that is, in the formula (5), the total carbon number of the R ⁵ C, R ⁶ C and R ⁷ C portions is 12 At the time, the IOB is 0.60. Therefore, when the total number of carbon atoms of the fatty acid in the glycerin and the fatty acid triester is about 12 or more, the requirement of IOB of about 0.00 to about 0.60 is satisfied. The above-mentioned triglyceride of glycerin and fatty acid is a so-called fat, and it is a component which comprises a human body, and it is preferable from a safety viewpoint.

Examples of the above-mentioned glycerin and fatty acid triesters include tricocohol fatty acid glyceride, NA36, Panaseto 800, Panaseto 800B, and Panaseto 810S, and three C2L oil fatty acid glycerides and tri-CL oil fatty acid glycerides (above Oil Co., Ltd.) and so on.

The diester of glycerin and fatty acid is also called diglyceride, and examples thereof include a diester of glycerin and capric acid (C ₁₀ ), a diester of glycerin and dodecanoic acid (C ₁₂ ), and glycerin and palmitic acid. a diester of (C ₁₆ ), a diester of glycerin and two fatty acids, and mixtures thereof.

In the diester of the glycerin and the fatty acid, the carbon number of the fatty acid constituting the diester of glycerin and the fatty acid is total, that is, in the formula (6), when the total carbon number of the R ⁵ C and R ⁶ C moieties is 16, the IOB is 0.58. Therefore, in the diester of the glycerin and the fatty acid, when the total carbon number of the fatty acid is about 16 or more, the requirement of IOB of about 0.00 to about 0.60 is satisfied.

The monoester of the above glycerin and a fatty acid is also called a monoglyceride, and examples thereof include a monoalcoholic acid (C ₂₀ ) monoglyceride of glycerin and a behenic acid (C ₂₂ ) monoester of glycerin.

In the monoester of the glycerin and the fatty acid, the carbon number of the fatty acid constituting the monoester of glycerin and the fatty acid, that is, in the formula (7), when the carbon number of the R ⁵ C moiety is 19, the IOB is 0.59. Therefore, in the monoester of the above glycerin and fatty acid, when the carbon number of the fatty acid is about 19 or more, the requirement of IOB of about 0.00 to about 0.60 is satisfied.

[(a ₃ ) an ester of a chain hydrocarbon diol with at least one fatty acid]

Examples of the ester of the chain hydrocarbon diol and at least one fatty acid include a C ₂ -C ₆ chain hydrocarbon diol, and examples thereof include C ₂ to C ₆ glycols, and examples thereof include exemplified a monoester or diester of an alcohol, propylene glycol, butylene glycol, pentanediol or hexanediol with a fatty acid.

Specifically, examples of the ester of the chain hydrocarbon diol and at least one fatty acid include the following formula (8): R ⁸ COOC _k H _2k OCOR ⁹ (8) (wherein k is 2 to 6) An integer, and R ⁸ and R ^{9 are} each a chain hydrocarbon; a diester of a C ₂ -C ₆ glycol and a fatty acid, and the following formula (9): R ⁸ COOC _k H _2k OH (9) (where k It is an integer of 2 to 6, and R ⁸ is a linear hydrocarbon of a C ₂ -C ₆ glycol and a monoester of a fatty acid.

Among the above esters of C ₂ -C ₆ glycol and fatty acid, as the fatty acid to be esterified (corresponding to R ⁸ COOH and R ⁹ COOH in the formulas (8) and (9)), C ₂ to C ₆ glycol The ester with a fatty acid is not particularly limited as long as it satisfies the requirements of the above-mentioned IOB, melting point, and water solubility, and examples thereof include fatty acids listed in "(a ₁ ) chain hydrocarbon tetraol and at least one fatty acid ester". Saturated fatty acids and unsaturated fatty acids are exemplified, and saturated fatty acids are preferred in view of the possibility of denaturation by oxidation or the like.

In the diester of the butanediol (k=4) and the fatty acid represented by the formula (8), when the total carbon number of the R ⁸ C and R ⁹ C moieties is 6, the IOB is 0.60. Therefore, in the diester of the butanediol (k=4) and the fatty acid represented by the formula (8), when the total carbon number is about 6 or more, the requirement that the IOB is from about 0.00 to about 0.60 is satisfied. Further, in the monoester of ethylene glycol (k=2) and the fatty acid represented by the formula (9), when the carbon number of the R ⁸ C moiety is 12, the IOB is 0.57. Therefore, in the monoester of ethylene glycol (k=2) and fatty acid represented by formula (9), when the carbon number of the fatty acid is about 12 or more, the requirement of IOB of about 0.00 to about 0.60 is satisfied.

When the ester of C ₂ -C ₆ glycol and a fatty acid is considered to be denatured by oxidation or the like, an ester of a C ₂ -C ₆ glycol and a fatty acid derived from a saturated fatty acid, that is, C _{2 is used.} The ester of ~C ₆ glycol and saturated fatty acid is preferred.

Further, as the ester of the C ₂ -C ₆ glycol and the fatty acid, in order to make the IOB smaller and to improve the hydrophobicity, an ester derived from a glycol having a large carbon number and a fatty acid may, for example, be derived from butanediol. An ester of a glycol and a fatty acid of pentanediol or hexanediol is preferred.

Further, as the ester of the C ₂ -C ₆ glycol and the fatty acid, it is preferable to make the IOB smaller and to improve the hydrophobicity. For example, compole BL, compole BS (manufactured by Nippon Oil Co., Ltd.), and the like are mentioned as a commercial product of the above-mentioned ester of a C ₂ -C ₆ -glycol and a fatty acid.

[(B) (B1) has a chain hydrocarbon moiety and a compound of 2 to 4 hydroxyl groups which replaces the hydrogen atom of the above-mentioned chain hydrocarbon moiety, and (B2) has a chain hydrocarbon moiety and a hydrogen atom which substitutes the above-mentioned chain hydrocarbon moiety. Ether of a hydroxy compound]

(B) (B1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups which replace the hydrogen atom of the above-mentioned chain hydrocarbon moiety, and (B2) 1 having a chain hydrocarbon moiety and a hydrogen atom replacing the above chain hydrocarbon moiety The ether of the hydroxyl group compound (hereinafter sometimes referred to as "compound (B)") may have only the above IOB, melting point and water solubility, and all of the hydroxyl groups may not be etherified.

(B1) The compound having a chain hydrocarbon moiety and a 2-4 hydroxyl group which replaces the hydrogen atom of the above-mentioned chain hydrocarbon moiety is exemplified as the compound (A1) in the "compound (A)", for example, Pentaerythritol, glycerin, and glycol are mentioned.

(B2) a compound having a chain hydrocarbon moiety and one hydroxyl group replacing a hydrogen atom of the above-mentioned chain hydrocarbon moiety (hereinafter sometimes referred to as "compound (B2)"), for example, one hydrogen atom of a hydrocarbon may be mentioned The compound substituted with one hydroxy group (-OH) may, for example, be an aliphatic monohydric alcohol, and examples thereof include a saturated aliphatic monohydric alcohol and an unsaturated aliphatic monohydric alcohol.

Examples of the saturated aliphatic monohydric alcohol include a C ₁ to C ₂₀ saturated aliphatic monohydric alcohol, and examples thereof include methyl alcohol (C ₁ ) (C ₁ represents a carbon number, the same applies hereinafter), and ethyl group. Examples of the alcohol (C ₂ ), the propyl alcohol (C ₃ ), and the isomers thereof include isopropyl alcohol (C ₃ ), butyl alcohol (C ₄ ), and isomers thereof, and examples thereof include sec. - butyl alcohol (C ₄ ) and tert-butyl alcohol (C ₄ ), pentyl alcohol (C ₅ ), hexyl alcohol (C ₆ ), heptyl alcohol (C ₇ ), octyl alcohol (C ₈ ) and isomers thereof, include 2-ethylhexyl alcohol (C _8), nonyl alcohol (C _9), decyl alcohol (C _10), dodecyl alcohol (C _12), myristyl Alcohol (C ₁₄ ), cetyl alcohol (C ₁₆ ), heptadecyl alcohol (C ₁₇ ), stearyl alcohol (C ₁₈ ), and eicosyl alcohol (C ₂₀ ), and not enumerated These isomers.

The unsaturated aliphatic monohydric alcohol may be one in which one of the CC single bonds of the saturated aliphatic monohydric alcohol is replaced by a C=C double bond, and examples thereof include oleyl alcohol, and for example, new Japan may be mentioned. The trade names of the names of the RIKACOL series and UNJECOL series purchased by Physicochemical Co., Ltd.

The compound (B) may, for example, be an ether of (b ₁ ) a chain hydrocarbon tetraol and at least one aliphatic monohydric alcohol, and examples thereof include a monoether, a diether, a triether and a tetraether, and preferably Diether, triether and tetraether, more preferably triether and tetraether, particularly good tetraether, (b ₂ ) chain hydrocarbon triol and at least one aliphatic monohydric alcohol ether, for example, monoether And a diether and a triether, preferably a diether and a triether, more preferably a triether and a (b ₃ ) chain hydrocarbon diol and an ether of at least one aliphatic monohydric alcohol, and examples thereof include a monoether and The diether is preferably a diether.

Examples of the ether of the chain hydrocarbon tetraol and at least one aliphatic monohydric alcohol include the following formulas (10) to (13): (wherein, R ¹⁰ to R ^{13 are} each a chain hydrocarbon) pentaerythritol and an aliphatic monohydric alcohol tetraether, a triether, a diether, and a monoether.

Examples of the ether of the chain hydrocarbon triol and at least one aliphatic monohydric alcohol include the following formulas (14) to (16): (wherein, R ¹⁴ to R ^{16 are} each a chain hydrocarbon) glycerol and an aliphatic monohydric alcohol triether, diether and monoether.

The ether of the chain hydrocarbon diol and at least one aliphatic monohydric alcohol may, for example, be the following formula (17): R ¹⁷ OC _n H _2n OR ¹⁸ (17) (wherein n is an integer of 2 to 6) And R ¹⁷ and R ^{18 are} each a chain hydrocarbon; a diether of a C ₂ -C ₆ glycol and an aliphatic monohydric alcohol; and the following formula (18): R ¹⁷ OC _n H _2n OH (18) Wherein, n is an integer of 2 to 6, and R ¹⁷ is a chain hydrocarbon; a monoether of a C ₂ -C ₆ glycol and an aliphatic monohydric alcohol.

In the tetraether of the pentaerythritol and the aliphatic monohydric alcohol, the total number of carbon atoms of the aliphatic monohydric alcohol constituting the tetraether of the pentaerythritol and the aliphatic monohydric alcohol is R ¹⁰ , R ¹¹ , and R in the above formula (10). ^{When the} total carbon number of the ¹² and R ¹³ portions is 4, the IOB is 0.44. Therefore, in the tetraether of the pentaerythritol and the aliphatic monohydric alcohol, when the carbon number of the aliphatic monohydric alcohol is about 4 or more in total, the requirement of IOB of about 0.00 to about 0.60 is satisfied.

In the triether of the pentaerythritol and the aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the triether of the pentaerythritol and the aliphatic monohydric alcohol is a total of R ¹⁰ , R ¹¹ and R in the above formula (11). ^{When the} total carbon number of the ¹² parts is 9, the IOB is 0.57. Therefore, in the triether of the pentaerythritol and the aliphatic monohydric alcohol, when the total number of carbon atoms of the aliphatic monohydric alcohol is about 9 or more, the requirement of IOB of about 0.00 to about 0.60 is satisfied.

In the diether of the pentaerythritol and the aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the diether of the pentaerythritol and the aliphatic monohydric alcohol is a total of R ¹⁰ and R ¹¹ in the above formula (12). When the total carbon number is 15, the IOB is 0.60. Therefore, in the diether of the pentaerythritol and the aliphatic monohydric alcohol, when the total number of carbon atoms of the aliphatic monohydric alcohol is about 15 or more, the requirement of IOB of about 0.00 to about 0.60 is satisfied.

In the monoether of the pentaerythritol and the aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the monoether of the pentaerythritol and the aliphatic monohydric alcohol, that is, in the above formula (13), the carbon number of the R ¹⁰ moiety is 22 At the time, the IOB is 0.59. Therefore, in the monoether of the pentaerythritol and the aliphatic monohydric alcohol, when the carbon number of the aliphatic monohydric alcohol is about 22 or more, the requirement of IOB of about 0.00 to about 0.60 is satisfied.

Further, in the triether of the glycerin and the aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the triether of the glycerin and the aliphatic monohydric alcohol is a total of R ¹⁴ and R ¹⁵ in the formula (14). When the total carbon number of the R ¹⁶ portion is 3, the IOB is 0.50. Therefore, in the triether of the glycerin and the aliphatic monohydric alcohol, when the total number of carbon atoms of the aliphatic monohydric alcohol is about 3 or more, the requirement of IOB of about 0.00 to about 0.60 is satisfied.

In the diether of the glycerin and the aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the diether of glycerin and the aliphatic monohydric alcohol, that is, the carbon of the R ¹⁴ and R ¹⁵ moieties in the formula (15) When the total number is 9, the IOB is 0.58. Therefore, in the diether of the glycerin and the aliphatic monohydric alcohol, when the total number of carbon atoms of the aliphatic monohydric alcohol is about 9 or more, the requirement of IOB of about 0.00 to about 0.60 is satisfied.

In the monoether of the glycerin and the aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the monoether of glycerin and the aliphatic monohydric alcohol, that is, in the formula (16), when the carbon number of the R ¹⁴ moiety is 16 The IOB is 0.58. Therefore, in the monoether of the above glycerin and the aliphatic monohydric alcohol, when the carbon number of the aliphatic monohydric alcohol is about 16 or more, the requirement of IOB of about 0.00 to about 0.60 is satisfied.

In the diether of the butanediol (n=4) represented by the formula (17) and the diester of the aliphatic monohydric alcohol, when the total carbon number of the R ¹⁷ and R ¹⁸ moieties is 2, the IOB is 0.33. Therefore, in the diether of the butanediol (n=4) represented by the formula (17) and the diester of the aliphatic monohydric alcohol, when the total carbon number of the aliphatic monohydric alcohol is 2 or more, the requirement of satisfying IOB of about 0.00 to about 0.60 is satisfied. . Further, in the monoether of ethylene glycol (n = 2) represented by the formula (18) and the aliphatic monohydric alcohol, when the carbon number of the R ¹⁷ moiety is 8, the IOB is 0.60. Therefore, in the monoether of ethylene glycol (n=2) represented by the formula (18) and the aliphatic monohydric alcohol, when the carbon number of the aliphatic monohydric alcohol is about 8 or more, the requirement of IOB of about 0.00 to about 0.60 is satisfied.

As the compound (B), the compound (B1) and the compound (B2) can be produced by dehydration condensation in the presence of an acid catalyst.

[(C)(C1) a carboxylic acid, a hydroxy acid, an alkoxy acid or a carbonyl acid having a chain hydrocarbon moiety and a hydrogen atom of 2 to 4 groups replacing the hydrogen atom of the above-mentioned chain hydrocarbon moiety, and (C2) having a chain hydrocarbon An ester of a compound partially substituted with a hydroxyl group of a hydrogen atom of the above-mentioned chain hydrocarbon moiety]

(C) (C1) a carboxylic acid, a hydroxy acid, an alkoxy acid or a carbonyl acid having a chain hydrocarbon moiety and a hydrogen atom of 2 to 4 groups replacing the hydrogen atom of the above chain hydrocarbon moiety, and (C2) having a chain hydrocarbon moiety An ester of a compound which replaces one hydroxyl group of a hydrogen atom of the above-mentioned chain hydrocarbon moiety (hereinafter sometimes referred to as "compound (C)") has only the above IOB, melting point and water solubility, and all carboxyl groups. It may also be unesterified.

(C1) a carboxylic acid, a hydroxy acid, an alkoxy acid or a carbonyl acid containing a chain hydrocarbon moiety and a 2-4 carboxyl group which replaces the hydrogen atom of the above-mentioned chain hydrocarbon moiety (hereinafter sometimes referred to as "compound (C1)" For example, a chain hydrocarbon carboxylic acid having 2 to 4 carboxyl groups may be mentioned, and examples thereof include a chain hydrocarbon dicarboxylic acid, and examples thereof include an alkane dicarboxylic acid, and examples thereof include ethane dicarboxylic acid and propane. Diacid, butanedioic acid, pentanedioic acid, hexanedioic acid, heptanedioic acid, octanedioic acid, decanedioic acid and decanedioic acid, chain hydrocarbon tricarboxylic acid, for example, an alkane Examples of the tricarboxylic acid include propane triacid, butane tricarboxylic acid, pentane tricarboxylic acid, hexane tricarboxylic acid, heptane tricarboxylic acid, octane tricarboxylic acid, decanetricarboxylic acid, and decanetricarboxylic acid, and a chain shape. Examples of the hydrocarbon tetracarboxylic acid include an alkanetetracarboxylic acid, and examples thereof include butanetetracarboxylic acid, pentanetetracarboxylic acid, hexanetetracarboxylic acid, heptanetetracarboxylic acid, octane tetracarboxylic acid, decanetetracarboxylic acid, and decane. Tetraacid.

Further, the chain hydrocarbon hydroxy acid having 2 to 4 carboxyl groups in the compound (C1) may, for example, be a chain hydrocarbon alkoxy acid having 2 to 4 carboxyl groups such as malic acid, tartaric acid, citric acid or isocitric acid. For example, it contains O-acetyl citrate and a chain hydrocarbon carbonyl acid having 2 to 4 carboxyl groups. (C2) A compound having a chain hydrocarbon moiety and a hydroxyl group which replaces the hydrogen atom of the chain hydrocarbon moiety, and examples of the "compound (B)" may be mentioned, and examples thereof include aliphatic monohydric alcohol. .

The compound (C) is (c ₁ ) an ester of a chain hydrocarbon tetracarboxylic acid having four carboxyl groups, a hydroxy acid, an alkoxy acid or a carbonyl acid and at least one aliphatic monohydric alcohol, and examples thereof include a monoester. And diesters, triesters and tetraesters, preferably diesters, triesters and tetraesters, more preferably triesters and tetraesters, particularly preferably tetraesters, (c ₂ ) chain hydrocarbons having 3 carboxyl groups The ester of a carboxylic acid, a hydroxy acid, an alkoxy acid or a carbonyl acid with at least one aliphatic monohydric alcohol may, for example, be a monoester, a diester or a triester, preferably a diester or a triester, more preferably And a (c ₃ ) chain hydrocarbon dicarboxylic acid having two carboxyl groups, a hydroxy acid, an alkoxy acid or a carbonyl acid, and an ester of at least one aliphatic monohydric alcohol, for example, a monoester And a diester, preferably a diester. Examples of the compound (C) include commercially available products such as dioctyl adipate and tributyl ethoxide.

[(D) having a chain hydrocarbon moiety and a CC single bond inserted in the above chain hydrocarbon moiety selected from an ether bond (-O-), a carbonyl bond (-CO-), an ester bond (-COO-), and carbonic acid Any one of the bonded compounds in the group of ester bonds (-OCOO-)

The (D) having a chain hydrocarbon moiety and a CC single bond inserted in the chain hydrocarbon moiety is selected from an ether bond (-O-), a carbon bond (-CO-), an ester bond (-COO-), and carbonic acid. A compound in which one of the groups of the ester bond (-OCOO-) is bonded (hereinafter sometimes referred to as "compound (D)"), and (d ₁ ) an aliphatic monohydric alcohol and an aliphatic monohydric alcohol are mentioned. An ether, a (d ₂ ) dialkyl ketone, an ester of a (d ₃ ) fatty acid and an aliphatic monohydric alcohol, and (d ₄ ) a dialkyl carbonate.

[(d ₁ ) an ether of an aliphatic monohydric alcohol and an aliphatic monohydric alcohol]

The ether of the aliphatic monohydric alcohol and the aliphatic monohydric alcohol may, for example, be a compound having the following formula (19): R ¹⁹ OR ²⁰ (19) (wherein each of R ¹⁹ and R ²⁰ is a chain hydrocarbon) .

The aliphatic monohydric alcohol constituting the ether (corresponding to R ¹⁹ OH and R ²⁰ OH in the formula (19)) is not particularly limited as long as it satisfies the requirements of the above IOB, melting point and water solubility, and is not particularly limited. The aliphatic monohydric alcohol exemplified in the item "Compound (B)" can be mentioned.

In the ether of the aliphatic monohydric alcohol and the aliphatic monohydric alcohol, the total number of carbon atoms of the aliphatic monohydric alcohol constituting the ether is, in the above formula (19), the total carbon number of the R ¹⁹ and R ²⁰ moieties is 2 The IOB is 0.50. Therefore, when the total number of carbon atoms is only about 2 or more, the requirements of the above IOB are satisfied. However, when the total carbon number is 6 or so, the water solubility is about 2 g, which is also problematic from the viewpoint of vapor pressure. In order to satisfy the requirement of water solubility of about 0.00 to about 0.05 g, it is preferred that the above carbon number is about 8 or more in total.

[(d ₂ )dialkyl ketone]

The dialkyl ketone may, for example, be a compound having the following formula (20): R ²¹ COR ²² (20) (wherein each of R ²¹ and R ²² is an alkyl group).

In the dialkyl ketone, when the total carbon number of R ²¹ and R ²² is 5, the IOB is 0.54, and the total carbon number is about 5 or more in total, which satisfies the requirements of the above IOB. However, when the total carbon number is 5, the water solubility is about 2 g. Therefore, in order to satisfy the requirement of water solubility of about 0.00 to about 0.05 g, the total carbon number is preferably about 8 or more. Further, in consideration of the vapor pressure, the carbon number is preferably about 10 or more, and more preferably about 12 or more.

Further, when the total carbon number is about 8, the 5-nonanone may have a melting point of about -50 ° C and a vapor pressure of about 230 Pa at 20 ° C. In addition to the above dialkyl ketone Other than that which can be obtained, it can be obtained by a known method, for example, by oxidizing a second-stage alcohol with chromic acid or the like.

[(d ₃ ) ester of fatty acid with aliphatic monohydric alcohol]

The ester of the fatty acid and the aliphatic monohydric alcohol may, for example, be a compound having the following formula (21): R ²³ COOR ²⁴ (21) (wherein each of R ²³ and R ²⁴ is a chain hydrocarbon).

The fatty acid constituting the above-mentioned ester (corresponding to R ²³ COOH in the formula (21)) may, for example, be a fatty acid as exemplified in the "(a ₁ ) chain hydrocarbon tetraol and fatty acid ester", and may be exemplified by saturation. When a fatty acid or an unsaturated fatty acid is considered to be likely to be denatured by oxidation or the like, a saturated fatty acid is preferred. The aliphatic monohydric alcohol (e.g., R ²⁴ OH in the formula (21)) constituting the above-mentioned ester may, for example, be an aliphatic monohydric alcohol as exemplified in the item "compound (B)".

Further, in the ester of the fatty acid and the aliphatic monohydric alcohol, the total number of carbon atoms of the fatty acid and the aliphatic monohydric alcohol is, in the formula (21), when the total carbon number of the R ²³ C and R ²⁴ moieties is 5, When the total carbon number of the R ²³ C and R ²⁴ portions is about 5 or more, the above-mentioned IOB requirements are satisfied. However, for example, in the butyl acetate having a total carbon number of 6 described above, the vapor pressure is 2,000 Pa which is extremely high. Therefore, in consideration of the vapor pressure, it is preferred that the total carbon number is about 12 or more. Further, when the total carbon number is about 11 or more, the water solubility is about 0.00 to about 0.05 g.

Examples of the ester of the above fatty acid and the aliphatic monohydric alcohol include, for example, an ester of dodecanoic acid (C ₁₂ ), dodecyl alcohol (C ₁₂ ), and myristic acid (C ₁₄ ). , and lauryl alcohol (C ₁₂₎ esters of as selling products of esters of fatty acids with aliphatic monohydric alcohols of, for example, include ErekutolWE20, and ErekutolWE40 (as above NOF Co., Ltd.).

[(d ₄ )Dialkyl carbonate]

The dialkyl carbonate may, for example, be a compound having the following formula (22): R ²⁵ OC(=O)OR ²⁶ (22) (wherein R ²⁵ and R ^{26 are} each an alkyl group).

In the above dialkyl carbonate, when the total carbon number of R ²⁵ and R ²⁶ is 6, the IOB is 0.57, and the total carbon number of R ²⁵ and R ²⁶ is about 6 or more to satisfy the requirements of IOB. When the water solubility is considered, the total carbon number of R ²⁵ and R ²⁶ is preferably about 7 or more, and preferably about 9 or more. The above dialkyl carbonates are commercially available, and can be synthesized by a reaction of phosgene with an alcohol, a reaction of a chloroformate with an alcohol or an alcoholate, and a reaction of silver carbonate with an alkyl iodide.

[(E) polyoxy C ₂ ~C ₆ alkanediol or its ester or ether]

The polyoxy C ₂ -C ₆ alkanediol or an ester thereof or an ether (hereinafter sometimes referred to as a compound (E)) may, for example, be (e ₁ ) a polyoxy C ₂ -C ₆ alkanediol or (e) ₂ ) an ester of polyoxy C ₂ -C ₆ alkanediol with at least one fatty acid, (e ₃ ) a polyoxy C ₂ -C ₆ alkanediol and an ether of at least one aliphatic monohydric alcohol, (e ₄ ) An ester of a polyoxy C ₂ -C ₆ alkanediol with a chain hydrocarbon tetracarboxylic acid, a chain hydrocarbon tricarboxylic acid or a chain hydrocarbon dicarboxylic acid, and (e ₅ ) a polyoxy C ₂ -C ₆ alkanediol An ether of a chain hydrocarbon tetraol, a chain hydrocarbon triol or a chain hydrocarbon diol. The following instructions.

[(e ₁ ) polyoxy C ₂ ~ C ₆ alkanediol]

The above polyoxy C ₂ -C ₆ alkanediol represents i) an oxygen C ₂ -C ₆ alkylene skeleton having a selected from the group consisting of an ethylene oxide skeleton, a propylene oxide skeleton, a butylene oxide skeleton, and an epoxy pentane. a skeleton having any one of a skeleton and an epoxy hexane skeleton, and having a hydroxyl group at both terminals, and ii) a block having two or more skeletons selected from the above group and having a hydroxyl group at both ends The copolymer or iii) has a random copolymer having two or more kinds of skeletons selected from the above group and having a hydroxyl group at both terminals.

The above oxygen C ₂ -C ₆ alkylene skeleton is derived from the viewpoint of lowering the IOB of the polyoxy C ₂ -C ₆ alkanediol, and is a propylene oxide skeleton, a butylene oxide skeleton, an epoxy pentane skeleton or an epoxy. The hexane skeleton is preferred, and a butylene oxide skeleton, an epoxypentane skeleton or an oxirane skeleton is preferred.

The polyoxy C ₂ -C ₆ alkanediol may be represented by the following formula (23): HO-(C _m H _2m O) _n -H (23) (wherein m is an integer of 2 to 6).

Further, after confirming by the inventors, in the case of polyethylene glycol (a homopolymer corresponding to m=2 in the formula (23)), when n≧45 (weight average molecular weight is more than 2,000), it satisfies about 0.00~. The requirements of the IOB of about 0.60, but even if the weight average molecular weight is more than about 4,000, the water solubility requirement is not met. Therefore, in the (e ₁ ) polyoxy C ₂ -C ₆ alkanediol, ethylene glycol is used as a block copolymer or random copolymer with other glycols in consideration of a homopolymer containing no ethylene glycol. Must be contained in (e ₁ ) polyoxy C ₂ ~ C ₆ alkanediol.

Therefore, the homopolymer of the formula (23) contains a homopolymer of propylene glycol, butylene glycol, pentanediol or hexanediol. From the above, in the formula (23), m is from about 3 to about 6, preferably from about 4 to about 6, and n is 2 or more.

For the above formula (23), the value of n is such that the poly C ₂ -C ₆ alkanediol has an IOB of about 0.00 to about 0.60, a melting point of about 45 ° C or less, and about 0.00 to about 0.05 for 100 g of water at 25 ° C. The value of the solubility of water in g.

For example, when the formula (23) is polypropylene glycol (a homopolymer of m=3), when n=12, the IOB becomes 0.58. Therefore, when the formula (23) is a polypropylene glycol (a homopolymer of m = 3), when m≧ is about 12, the above-mentioned requirements of the IOB are satisfied.

Further, when the formula (21) is polytetramethylene glycol (m=4 homopolymer), when n=7, IOB is 0.57. Therefore, when the formula (23) is polytetramethylene glycol (m=4 homopolymer), when n≧ is about 7, the above-mentioned IOB requirements are satisfied.

The polyoxy C ₂ -C ₆ alkanediol preferably has a weight average molecular weight of from about 200 to about 10,000, preferably from about 250 to about 8,000, more preferably from about 250 to about 10,000, from the viewpoint of IOB, melting point, and water solubility. A range of 5,000. Further, from the viewpoints of IOB, melting point and water solubility, the polyoxy C ₃ alkanediol, i.e., polypropylene glycol, preferably has a weight average molecular weight of from 1,000 to 10,000, preferably from about 3,000 to about 8,000, more preferably about 4,000 to about 5,000. When the weight average molecular weight is less than about 1,000, the water solubility cannot satisfy the requirements, and the larger the weight average molecular weight, the more the absorption speed of the absorbent body and the whiteness of the surface sheet tend to increase.

As a commercial item of the above-mentioned polyoxy C ₂ -C ₆ alkanediol, for example, Uno Road (trademark) D-1000, D-1200, D-2000, D-3000, D-4000, PB-500 , PB-700, PB-1000 and PB-2000 (above are Nippon Oil Co., Ltd.).

[(e ₂ ) an ester of a polyoxy C ₂ -C ₆ alkanediol with at least one fatty acid]

Examples of the polyoxy C ₂ ~ C ₆ alkylene glycol and at least one fatty acid esters include the "(e ₁₎ polyoxy C ₂ ~ C ₆ alkanediol" as described in Paragraph of polyoxy C ₂ ~ One or both of the OH terminals of the C ₆ alkanediol may be esterified with a fatty acid, and monoesters and diesters may be mentioned.

The ester of a polyoxy C ₂ -C ₆ alkanediol and at least one fatty acid, as a fatty acid to be esterified, for example, "(a ₁ ) chain hydrocarbon tetraol and at least one fatty acid ester" The fatty acid to be enumerated may, for example, be a saturated fatty acid or an unsaturated fatty acid, and in view of the possibility of denaturation by oxidation or the like, a saturated fatty acid is preferred. For example, WILBRIDE cp9 (manufactured by Nippon Oil Co., Ltd.) can be mentioned as a commercial product of the above-mentioned ester of a polyoxy C ₂ -C ₆ alkanediol and a fatty acid.

[(e ₃ ) an ether of a polyoxy C ₂ -C ₆ alkanediol and at least one aliphatic monohydric alcohol]

Examples of the ether of the polyoxy C ₂ -C ₆ alkanediol and at least one aliphatic monohydric alcohol include polyoxygen as described in the section "(e ₁ ) polyoxy C ₂ -C ₆ alkanediol". One or both of the OH terminals of the C ₂ -C ₆ alkanediol may be etherified by an aliphatic monohydric alcohol, and examples thereof include a monoether and a diether. The ether of the polyoxy C ₂ -C ₆ alkanediol and the at least one aliphatic monohydric alcohol, as the aliphatic monohydric alcohol to be etherified, for example, the fat listed in the item "Compound (B)" Family 1 alcohol.

[(e ₄ ) an ester of a polyoxy C ₂ -C ₆ alkanediol with a chain hydrocarbon tetracarboxylic acid, a chain hydrocarbon tricarboxylic acid or a chain hydrocarbon dicarboxylic acid]

An ester of the above polyoxy C ₂ -C ₆ alkanediol with a chain hydrocarbon tetracarboxylic acid, a chain hydrocarbon tricarboxylic acid or a chain hydrocarbon dicarboxylic acid as a polyoxy C ₂ -C ₆ alkane to be esterified alcohol include "(e ₁₎ polyoxy C ₂ ~ C ₆ alkanediol" described the polyoxy C ₂ ~ C ₆ alkanediol item. Moreover, as a chain hydrocarbon tetracarboxylic acid, a chain hydrocarbon tricarboxylic acid, and a chain hydrocarbon dicarboxylic acid to be esterified, the term "compound (C)" can be mentioned.

The ester of the above polyoxy C ₂ -C ₆ alkanediol with a chain hydrocarbon tetracarboxylic acid, a chain hydrocarbon tricarboxylic acid or a chain hydrocarbon dicarboxylic acid, which may be obtained by a chain hydrocarbon tetracarboxylic acid, in addition to the commercially available The chain hydrocarbon tricarboxylic acid or the chain hydrocarbon dicarboxylic acid is produced by polycondensing an oxygen C ₂ -C ₆ alkanediol under known conditions.

[(e ₅ ) an ether of a polyoxy C ₂ -C ₆ alkanediol with a chain hydrocarbon tetraol, a chain hydrocarbon triol or a chain hydrocarbon diol]

The polyoxy C ₂ -C ₆ alkanediol and the ether of the chain hydrocarbon tetraol, the chain hydrocarbon triol or the chain hydrocarbon diol may be used as the polyoxy C ₂ -C ₆ alkanediol to be etherified. include "(e ₁₎ polyoxy C ₂ ~ C ₆ alkanediol" described the polyoxy C ₂ ~ C ₆ alkanediol item. In addition, as the chain hydrocarbon tetraol, the chain hydrocarbon triol, and the chain hydrocarbon diol to be etherified, the term "compound (A)" can be mentioned, and examples thereof include pentaerythritol, glycerin, and Glycol.

As a commercial product of the above-mentioned polyoxy C ₂ -C ₆ alkanediol and a chain hydrocarbon tetraol, a chain hydrocarbon triol or a chain hydrocarbon diol, for example, UNILUB (trademark) 5TP-300KB, and excellent Neo Road (trademark) TG-3000 and TG-4000 (made by Nippon Oil Co., Ltd.). UNILUB (trademark) 5TP-300KB is a compound in which propylene glycol 65 mole and polyethylene glycol 5 mole are polycondensed in pentaerythritol 1 molar, the IOB is 0.39, the melting point is less than 45 ° C, and the water solubility is less than 0.05. g.

Unio Road (trademark) TG-3000 is a compound in which propylene glycol 50 mole is polycondensed in glycerol 1 molar, the IOB is 0.42, the melting point is less than 45 ° C, the water solubility is less than 0.05 g, and the weight average The molecular weight is about 3,000. Unio Road (trademark) TG-4000 is a compound in which propylene glycol 70 mole is polycondensed in glycerol 1 molar, the IOB is 0.40, the melting point is less than 45 ° C, the water solubility is less than 0.05 g, and the weight average The molecular weight is about 4,000. .

The above polyoxy C ₂ -C ₆ alkanediol and an ether of a chain hydrocarbon tetraol, a chain hydrocarbon triol or a chain hydrocarbon diol may be due to a chain hydrocarbon tetraol, a chain hydrocarbon triol or a chain hydrocarbon In the alcohol, a C ₂ -C ₆ alkylene oxide is produced by an addition reaction under known conditions.

[(F) chain hydrocarbon]

The above chain hydrocarbon is because the above inorganic value is 0, so the IOB is 0.00. The water solubility is almost 0 g, or the melting point is about 45 ° C or less, that is, contained in the above blood modifying agent. Examples of the chain hydrocarbons include, for example, a (f1) chain alkane, for example, a linear alkane or a branched alkane. For example, in the case of a linear alkane, when the melting point is about 45 ° C or lower, the carbon number is substantially 22 or less. By. Further, when the vapor pressure is considered, it basically contains a carbon number of 13 or more. In the case of a branched alkane, the melting point of the linear alkane is lower than that of the linear alkane, so that the carbon number is 22 or more. As a commercial item of the said hydrocarbon, PARLEAM6 (Nippon Oil Co., Ltd.) is mentioned, for example.

The above-mentioned blood modifying agent was discussed in detail in conjunction with the examples and found to have at least a function of lowering blood viscosity and surface tension. The menstrual blood to be absorbed by the absorbent article is compared with the general blood, and contains proteins such as the endometrial wall, so that the blood cells will act in conjunction with each other to easily cause the blood cells to be in a rouleau formation state. Therefore, the menstrual blood to be absorbed by the absorbent article tends to become highly viscous, and if the surface sheet is non-woven or woven, the menstrual blood is easily blocked between the fibers, which tends to make the wearer feel sticky, and the surface of the surface sheet is diffused by menstrual blood. And easy to leak. On the other hand, by applying the blood modifying agent of the present invention to the surface layer sheet, the blood of the surface layer sheet is not easily hindered by the blood, and the menstrual blood sheet can be quickly moved from the surface layer sheet to the absorber.

Further, since the blood modifying agent of the present invention having an IOB of about 0.00 to about 0.60 has high organicity and easily enters between blood cells, the blood cells can be stabilized, and the blood cells are less likely to form a rouleau formation structure. The blood modifying agent of the invention can stabilize the blood cells, and the blood cells are not easy to form a rouleau formation structure, so the absorbent body is easy to suck. Receipt blood. For example, an acrylic high-absorbent polymer is known. When an absorbent article containing SAP is used, when blood is absorbed, a blood cell showing a rouleau formation covers the surface of the SAP, making it difficult for SAP to exhibit absorption performance, but by stabilizing The blood cells can make SAP easy to absorb. Further, since the blood modifying agent having high affinity with red blood cells protects the red blood cell membrane, the red blood cells are not easily broken.

The coating per unit area of the blood modifying agent for the surface sheet 2 is preferably from 1 to 30 g/m ² , more preferably from 3 to 10 g/m ² . When the mass ratio of the blood modifying agent per unit area is 1 g/m ² hours, it may be difficult to stably apply the blood modifying agent to the surface sheet 2, and if the mass ratio of the blood modifying agent per unit area is 30 g/m. ^{At 2} o'clock, the surface sheet 2 sometimes has a muddy condition.

After the blood modifying agent is heated to a desired temperature, it is applied to the surface sheet 2 using a contact coater such as a slot coater or a non-contact applicator such as a spray coater, a curtain coater, or a spiral coater. Since the blood modifying agent application region 8 can be uniformly dispersed as a point of the droplet-shaped blood modifying agent, and the surface sheet 2 is not damaged, the blood modifying agent is coated using a non-contact applicator. It is better for the surface sheet 2 .

When a non-woven fabric for a surface sheet is produced, a blood modifying agent may be applied to the nonwoven fabric. Further, in the manufacturing step of the absorbent article 1, a blood modifying agent can be applied to the surface sheet 2. However, it is preferable that the blood modifying agent is applied to the surface sheet 2 in the manufacturing step of the absorbent article 1 from the viewpoint of suppressing investment in equipment. Further, between the manufacturing steps of the absorbent article 1, it is intended to suppress the blood modifying agent applied to the surface sheet 2 It is preferable to reduce the application of the blood modifying agent to the surface sheet 2 in the step of completing the completion of the absorbent article 1. For example, a blood modifying agent may be applied to the surface sheet 2 before the step of packaging the absorbent article 1.

Fig. 5 shows a view of the absorbent article 1 to which the wing portion 6 to be packaged is folded. When the absorbent article 1 having the above constituent elements is packaged, as shown in Fig. 5, the pair of wing portions 6 are folded inward in the width direction.

The adhesive portion 7 is covered by the release sheet 33. Thereby, the pre-use adhesive portion 7 of the absorbent article 1 can be protected. The release sheet 33 is only required to be a sheet which is peelable to the adhesive of the adhesive portion 7, and is not particularly limited. For the release sheet 33, for example, a release agent may be applied to the substrate. The substrate on which the release agent is applied may be a film such as polypropylene, low-density polyethylene or polyvinyl alcohol, non-woven fabric, paper or the like, and the release agent is polyfluorene-based, fluorine-based or isocyanate.

As shown in FIG. 5, when the absorbent article 1 is packaged, the absorbent article 1 of the folded wing portion 6 is dispensed onto the packaging material 31. The packaging material 31 is, for example, a nonwoven fabric or a resin film. Further, a stop band 32 is provided at the long end of the packaging material 31. The absorbent article 1 disposed on the packaging material 31 is folded together with the packaging material 31 along the B-B line and the C-C line in the longitudinal direction (Y direction). Then, the stop tape 32 is used to maintain the folded state of the absorbent article 1. On the other hand, together with the absorbent article 1, the both sides 31a in the width direction of the folded packaging material 31 are joined by hot embossing. Thereby, the packaged product 30 shown in FIG. 6 containing the absorbent article 1 is manufactured. Fig. 6 is a perspective view showing a package 30 containing an absorbent article.

Fig. 7 is a schematic cross-sectional view showing a cross section taken along line D-D of Fig. 5; As shown in Fig. 7, the side panel layer 5 of the wing portion 6 when the wing portion 6 is folded is brought into contact with the blood modifying agent application region 18 (see Fig. 1) of the surface layer sheet 2. In the blood modifying agent application region 18, since the blood modifying agent is applied, the surface sheet 2 in the wing portion 6 comes into contact with the blood modifying agent. However, by the projection 21 of the surface sheet 2, the contact area of the side sheet layer 5 in the wing portion 6 and the blood modifying agent application region 18 of the surface sheet 2 becomes small. Thereby, the blood modifying agent in the blood modifying agent application region 18 is infiltrated into the wing portion 6, and the weakening of the bonding force between the surface sheet 2 and the back sheet 3 in the wing portion 6 can be suppressed. Further, the blood modifying agent in the blood modifying agent application region 18 is transferred to the side panel layer 5 of the wing portion 6, and the amount of the blood modifying agent in the blood modifying agent application region 18 can be suppressed from decreasing.

As described above, the fiber density of the central portion 23 of the projection 21 is lower than the fiber density of the side portion 24 and/or the recess portion 22 of the projection 21 (see Fig. 3). However, the blood modifying agent applied to the blood modifying agent application region 18 of the surface sheet 2 tends to concentrate on the higher density of the surface sheet 2. In the surface sheet 2, the fiber density of the central portion 23 of the projection 21 which is in contact with the wing portion 6 is lower than the side portion of the projection 21 and the concave portion 22, so that the blood is not concentrated in the central portion 23 of the projection 21. Quality agent. Therefore, by reducing the fiber density of the central portion 23 of the projection 21, the blood modifying agent transferred to the wing portion 6 can be further reduced as compared with the fiber density of the side portion 24 and/or the concave portion 22 of the projection 21. the amount.

The absorbent article 1 according to the embodiment of the present invention described above can be formed as follows.

(1) The top sheet 2A shown in Fig. 8 is on the top sheet 2A The recess 22A can form the opening portion 26A. Fig. 8(a) is a perspective view showing an enlarged portion, a concave portion, and an opening portion formed in the surface sheet 2, and Fig. 8(b) is a plan view showing an enlarged portion, a concave portion, and an opening portion formed in the surface sheet 2. The fiber density on the side surface of the opening portion 26A is preferably higher than the fiber density of the central portion 23A of the projection portion 21A. As a result, the blood modifying agent applied to the surface sheet is aggregated around the opening portion 26A of the concave portion 22A, so that the central portion 23 of the protruding portion 21 that is in contact with the wing portion 6 does not collect too much blood. Modifier. Therefore, when the fiber density on the side surface of the opening portion 26A is higher than the fiber density of the central portion 23A of the projection portion 21A, the amount of the blood modifying agent transferred to the wing portion 6 when the wing portion 6 is folded can be reduced. Thereby, the blood modifying agent applied to the surface sheet 2A is allowed to permeate into the wing portion 6, and the side sheet layer 5 constituting the wing portion 6 can be prevented from being peeled off from the back sheet 3.

For example, as shown in FIG. 9, a plurality of elongated members 160 which are arranged in the machine direction (MD) and have no air permeability, which are extended in the width direction (CD), are provided in the mesh supporting member 130, and can be applied to the surface sheet 2A. The recess 22A forms the opening 26A. In the portion where the elongated member 160 of the mesh supporting member 130 is not provided, the gas 141 ejected from the blowing portion 140 passes through the mesh supporting member 130, and the fibers of the network 120 can be distracted to the extent that the mesh 120 is formed in the groove 120. On the other hand, in the portion where the elongated member 160 of the mesh supporting member 130 is provided, the gas 141 ejected from the blowing portion 140 does not pass through the mesh supporting member 130, and the elongated member 160 is stopped, so that the fibers of the network 120 are strongly dialed. The network 120 is opened to the extent that the opening is formed. Thereby, an opening is formed in the concave portion 22A of the surface sheet 2A. Part 26A. Since the fibers that are plucked are densely formed on the side surface of the opening portion 26A, the fiber density on the side surface of the opening portion 26A is increased.

(2) The surface sheet 2B shown in Fig. 10 is bent in a corrugated shape by the nonwoven fabric constituting the surface sheet 2B, and the surface sheet 2B can be extended in a predetermined direction, and the protruding portions 21B and the concave portions are formed in the intersecting direction of the predetermined direction. 22B. Fig. 10 is a schematic perspective view showing a modification of the surface sheet. For example, by passing a non-woven fabric between a pair of toothed rolls, a surface sheet 2B which is bent into a corrugated shape can be produced. Moreover, as shown in FIG. 11, the nonwoven fabric can be bent into a wave shape, and the opening portion 26C can be formed in the concave portion 22C of the surface sheet 2C forming the projection 21C and the recess 22C.

Fig. 11 (a) is a schematic perspective view showing a modification of the surface sheet, and Fig. 11 (b) is a schematic plan view showing a modification of the surface sheet. For example, between the protrusion roller having a plurality of protrusions having a shape such as a needle shape, a cylindrical shape, and a conical shape on the outer circumferential surface, and an anvil roller having a protrusion and a fitting concave portion at a position having a protrusion corresponding to the protrusion roller on the outer circumferential surface, The surface layer sheet in which the opening portion 26C is formed by the concave portion 22C can be manufactured by bending the non-woven fabric into a corrugated shape. Since the projection of the projection roller penetrates the nonwoven fabric to form the opening portion 26C, when the opening portion 26C is formed, the pressure is applied to the side surface of the opening portion 26C. Therefore, the fiber density on the side surface of the opening portion 26C is higher than the fiber density in the central portion 23C of the projection portion 21C. Therefore, since the blood modifying agent applied to the surface sheet 2C is collected on the side surface of the opening portion 26C of the concave portion 22C of the surface sheet 2C, when the wing portion 6 is folded, the amount of blood reforming transferred to the wing portion 6 is reduced. Thereby, the blood modifying agent applied to the surface sheet 2C is immersed in the wing portion 6, and the side sheet layer 5 constituting the wing portion 6 can be suppressed. The back sheet 3 is peeled off.

(3) As shown in Fig. 12, by forming the compressed portion 8D from the surface sheet 2D to the inside of the absorbent body 4D to the absorbent article 1D, the blood of the wing portion 6 and the surface sheet 2 when the wing portion 6 is folded can be changed. The contact area between the mass application regions 18 becomes small. Fig. 12 is a schematic cross-sectional view of the absorbent article 1D corresponding to the line A-A of Fig. 1. Thereby, when the wing portion 6 is folded, the blood reforming amount of the wing portion 6 transferred from the blood modifying agent application region 18 of the surface sheet 2 is reduced. The compression portion 8D formed in the absorbent article 1D may be a linear compression portion or a point compression portion. The compressing portion 8D can be formed, for example, by embossing to form the absorbent article 1D.

In the compression unit 8D, since the surface sheet 2D and the absorber 4D are compressed in the thickness direction, the density of the surface sheet 2D and the absorber 4D near the bottom of the compression unit 8D becomes high. Therefore, since the blood modifying agent applied to the surface sheet 2D is collected at the bottom of the compressed portion 8D, when the wing portion 6 is folded, the transfer of the wing portion 6 from the blood modifying agent application region 18 of the surface sheet 2 can be further reduced. The amount of blood modifying agent. Thereby, the blood modifying agent applied to the surface sheet 2D can be prevented from peeling off from the back sheet 3 by the side sheet layer 5 constituting the wing portion 6 by being infiltrated into the wing portion 6. When the compressed portion 8D is formed, when the surface sheet 2D of the compressed portion 8D is thinned, since the surface sheet 2D does not permeate the blood modifying agent, the surface sheet 2D in the compressed portion 8D is not thinned. good.

(4) The contact area between the blood modifying agent application region 18 of the surface sheet 2 and the wing portion 6 may be reduced, and the protrusion formed in the blood modifying agent application region 18 of the surface sheet 2 is not limited to the above-mentioned protrusion. unit. For example, the protrusions may be extended in the width direction (X direction), and the protrusions arranged side by side in the longitudinal direction (Y direction) may be provided in the blood modifying agent application region 18 of the surface sheet 2. Further, in the wavy form, the protrusion extending in the longitudinal direction (Y direction) or the width direction (X direction) may be provided in the blood modifying agent application region 18 of the surface sheet 2. Further, a protrusion having a shape such as a cylinder, a corner column, or a hemisphere is provided in the blood modifying agent application region 18 of the surface sheet 2.

(5) To further reduce the contact area between the blood modifying agent application region 18 and the wing portion 6 of the surface sheet 2, protrusions may be formed in the side sheet layer 5. For example, as shown in Fig. 13, the absorbent article 1E can be provided on the side panel layer 5E by the projection 51 which is formed by bending in a wave shape and extending in the longitudinal direction. Fig. 13 is a schematic cross-sectional view of the absorbent article 1E corresponding to the line A-A of Fig. 1. The protrusion formed in the blood modifying agent application region 18 of the surface sheet 2 is not limited to the above-described protrusion. Further, the protrusion extending in the width direction may be provided on the side panel layer. Further, a protrusion extending in the longitudinal direction or the wide direction in the wavy form may be provided on the side panel layer. Further, a protrusion of a shape such as a cylinder, a corner column, or a hemisphere may be provided on the side panel layer.

(6) The composition applied to the surface sheet is only a predetermined composition, and is not limited to the blood modifying agent. For example, an emulsion for preventing dry skin may be applied to the surface sheet.

[Examples]

In the present invention, since the blood modifying agent has a mechanism for lowering the viscosity and surface tension of the blood, the body fluid can be moved to the absorbent body 4 and then to the absorbent body by the blood modifying agent layer 24 not remaining on the surface layer sheet 2. 4 absorbed. By the following examples, it was confirmed that the blood modifying agent has a mechanism for lowering the viscosity and surface tension of blood.

〔example 1〕

[Evaluation of the rate of rewet and the migration speed of the absorber]

[Data of blood modifying agent]

Prepare the purchased sanitary napkins. The sanitary tampon is a surface sheet formed of a permeable non-woven fabric treated with a hydrophilic agent (composite fiber composed of polyester and polyethylene terephthalate, basic weight: 35 g/m ² ), and a woven non-woven fabric. (composite fiber made of polyester and polyethylene terephthalate, basic weight: 30g/m ² ) formed by the second sheet, pulp (basic weight: 150~450g/m ² , larger in the central part) ), an acrylic high-absorbent polymer (basis weight: 15 g/m ² ) and an absorbent core containing a tissue paper as a core wrap, a side sheet layer treated with a water repellent agent, and a back sheet formed of a polyethylene film.

The blood modifying agents used in the experiments are listed below.

[(a ₁ ) an ester of a chain hydrocarbon tetraol with at least one fatty acid]

‧Unistar H-408BRS, manufactured by Nippon Oil Co., Ltd.

Pentaerythritol tetraethyl 2-hexanoate, weight average molecular weight: about 640

‧Unistar H-2408BRS-22, manufactured by Nippon Oil Co., Ltd.

Mixture of pentaerythritol tetraethyl 2-ethylhexanoate and neopentyl glycol diethyl 2-hexanoate (58:42, weight ratio), weight average molecular weight: about 520

[(a ₂ ) an ester of a chain hydrocarbon triol with at least one fatty acid]

‧Cetiol SB45DEO, made by Japan Corning Co., Ltd.

Fatty acid is glycerol and fatty acid triester of oleic acid or stearic acid

‧SOY42, made by Nippon Oil Co., Ltd.

C ₁₄ fatty acid: C ₁₆ fatty acid: C ₁₈ fatty acid: C ₂₀ fatty acid (containing both saturated fatty acid and unsaturated fatty acid) contains glycerol and fatty acid triester in a weight ratio of 0.2:11:88:0.8. Weight average molecular weight: 880

‧Three C2L oil fatty acid glycerides, manufactured by Nippon Oil Co., Ltd.

C ₈ fatty acid: C ₁₀ fatty acid: C ₁₂ fatty acid is about 37:7:56 by weight of glycerin and fatty acid triester, weight average molecular weight: about 570

‧Three CL oil fatty acid glycerides, manufactured by Nippon Oil Co., Ltd.

C ₈ fatty acid: C ₁₂ fatty acid contains about glycerol and fatty acid triester in a weight ratio of 44:56, weight average molecular weight: about 570

‧Panaseto 810s, manufactured by Nippon Oil Co., Ltd.

C ₈ fatty acid: C ₁₀ fatty acid contains about glycerin and fatty acid triester in a weight ratio of 85:15, weight average molecular weight: about 480

‧Panaseto 800, manufactured by Nippon Oil Co., Ltd.

The fatty acids are octanoic acid (C ₈ ) glycerol and fatty acid triester, weight average molecular weight: about 470

‧Panaseto 800B, made by Nippon Oil Co., Ltd.

The fatty acids are 2-ethylhexanoic acid (C ₈ ) glycerol and fatty acid triester, weight average molecular weight: about 470

‧NA36, made by Nippon Oil Co., Ltd.

C ₁₆ fatty acid: C ₁₈ fatty acid: C ₂₀ fatty acid (containing both saturated fatty acid and unsaturated fatty acid) contains glycerin and fatty acid triester in a weight ratio of 5:92:3, weight average molecular weight: about 880

‧Three coconut oil fatty acid glycerides, manufactured by Nippon Oil Co., Ltd.

Fatty acids of C ₈ : C ₁₀ fatty acids: C ₁₂ fatty acids: C ₁₄ fatty acids: C ₁₆ fatty acids (containing both saturated and unsaturated fatty acids) are contained in a weight ratio of 4:8:60:25:3. Triglyceride of glycerol and fatty acid, weight average molecular weight: 670

‧ Caprylic acid diglyceride, manufactured by Nippon Oil Co., Ltd.

Fatty acid is a diester of glycerin and fatty acid of octanoic acid, weight average molecular weight: 340

[(a ₃ ) an ester of a chain hydrocarbon diol with at least one fatty acid]

‧compoleBL, made by Nippon Oil Co., Ltd.

Butyric acid (C ₁₂ ) monoester of butanediol, weight average molecular weight: about 270

‧compoleBS, made by Nippon Oil Co., Ltd.

Octadecanoic acid (C ₁₈ ) monoester of butanediol, weight average molecular weight: about 350

‧Unistar H-208BRS, manufactured by Nippon Oil Co., Ltd.

Diethyl 2-ethylhexanoate neopentyl glycol, weight average molecular weight: about 360

[(c ₂ ) an ester of a chain hydrocarbon tricarboxylic acid having three carboxyl groups, a hydroxy acid, an alkoxy acid or a carbonyl acid with at least one aliphatic monohydric alcohol]

‧O-Ethyl tributyl tributyl citrate, weight average molecular weight of Tokyo Chemical Industry Co., Ltd.: about 400

[(c ₃ ) an ester of a chain hydrocarbon dicarboxylic acid having two carboxyl groups, a hydroxy acid, an alkoxy acid or a carbonyl acid and at least one aliphatic monohydric alcohol]

‧ Dioctyl adipate, manufactured by Wako Pure Chemical Industries

Weight average molecular weight: about 380

[(d ₃ ) ester of fatty acid with aliphatic monohydric alcohol]

‧Erekutol WE20, made by Nippon Oil Co., Ltd.

Ester of dodecanoic acid (C ₁₂ ) and dodecyl alcohol (C ₁₂ ), weight average molecular weight: about 360

‧Erekutol WE40, made by Nippon Oil Co., Ltd.

Ester of tetradecanoic acid (C ₁₄ ) and dodecyl alcohol (C ₁₂ ), weight average molecular weight: about 390

[(e ₁ ) polyoxy C ₂ ~ C ₆ alkanediol]

‧Unio Road D-1000, made by Nippon Oil Co., Ltd.

Polypropylene glycol, weight average molecular weight: about 1,000

‧Unio Road D-1200, made by Nippon Oil Co., Ltd.

Polypropylene glycol, weight average molecular weight: about 1,200

‧Unio Road D-3000, made by Nippon Oil Co., Ltd.

Polypropylene glycol, weight average molecular weight: about 3,000

‧Unio Road D-4000, made by Nippon Oil Co., Ltd.

Polypropylene glycol, weight average molecular weight: about 4,000

‧Unio Road PB500, made by Nippon Oil Co., Ltd.

Polytetramethylene glycol, weight average molecular weight: about 500

‧Unio Road PB700, manufactured by Nippon Oil Co., Ltd.

Polybutylene oxide polyoxypropylene glycol, weight average molecular weight: about 700

‧Unio Road PB1000R, made by Nippon Oil Co., Ltd.

Polytetramethylene glycol, weight average molecular weight: about 1000

[(e ₂ ) an ester of a polyoxy C ₂ -C ₆ alkanediol with at least one fatty acid]

‧WILBRIDEcp9, made by Nippon Oil Co., Ltd.

a compound in which an OH group at both ends of polytetramethylene glycol is esterified with palmitic acid (C ₁₆ ), weight average molecular weight: about 1,150

[(e ₃ ) polyoxy C ₂ -C ₆ alkanediol and ether of at least one fatty acid]

‧UNILUB MS-70K, manufactured by Nippon Oil Co., Ltd.

Stearic acid decyl ether of polypropylene glycol, repeating unit of about 15, weight average molecular weight: about 1,140

[(e ₅ ) an ether of a polyoxy C ₂ -C ₆ alkanediol with a chain hydrocarbon tetraol, a chain hydrocarbon triol or a chain hydrocarbon diol]

‧UNILUB 5TP-300KB

Polyoxyethane polyoxypropylene pentaerythritol ether formed from pentaerythritol 1 molar addition to ethylene oxide 5 moles and propylene oxide 65 moles, weight average molecular weight: 4,130

‧Unio Road TG-3000, made by Nippon Oil Co., Ltd.

Glycerol ether of polypropylene glycol, repeating unit of about 16, weight average molecular weight: about 3,000

‧Unio Road TG-4000, made by Nippon Oil Co., Ltd.

Glycerol ether of polypropylene glycol, about 16 repeating units, weight average molecular weight: about 4,000

[(f ₁ )chain alkanes]

‧PARLEAM6, made by Nippon Oil Co., Ltd.

Copolymerization of isoparaffin, isobutylene and n-butene, followed by hydrogenation of branched hydrocarbons, the degree of polymerization: about 5 to about 10, weight average molecular weight: about 330

〔other materials〕

‧NA50, made by Nippon Oil Co., Ltd.

Adding hydrogen to NA36, reducing the ratio of double bonds of unsaturated fatty acids from raw materials to triglycerides of fatty acids, weight average molecular weight: about 880

‧(octanoic acid/tannic acid) monoglyceride, manufactured by Nippon Oil Co., Ltd.

Octanoic acid (C ₈ ) and citric acid (C ₁₀ ) are monoesters of glycerol and fatty acid contained in a weight ratio of 85:15, weight average molecular weight: about 220

‧Monomuls 90-L2 lauric acid monoglyceride, made by Japan Corning Co., Ltd.

‧Icyl citrate, manufactured by Tokyo Chemical Industry Co., Ltd.

Weight average molecular weight: about 230

‧Diisostearyl malate

Weight average molecular weight: about 640

‧Unio Road D-400, made by Nippon Oil Co., Ltd.

Polypropylene glycol, weight average molecular weight: about 400

‧PEG1500, made by Nippon Oil Co., Ltd.

Polyethylene glycol, weight average molecular weight: about 1,500 ~ about 1,600

‧Non-ion S-6, made by Nippon Oil Co., Ltd.

Polyethylene oxide monostearate, repeat unit of about 7, weight average molecular weight: about 880

‧WILBRIDEs753, made by Nippon Oil Co., Ltd.

Polyethylene oxide polyoxypropylene polybutylene oxide glycerol, weight average molecular weight: about 960

‧Unio Road TG-330, made by Nippon Oil Co., Ltd.

Glycerol ether of polypropylene glycol, repeating unit of about 6, weight average molecular weight: about 330

‧Unio Road TG-1000, made by Nippon Oil Co., Ltd.

Glycerol ether of polypropylene glycol, repeating unit of about 16, weight average molecular weight: about 1,000

‧UNILUB DGP-700, manufactured by Nippon Oil Co., Ltd.

Diglyceryl ether of polypropylene glycol, repeating unit of about 9, weight average molecular weight: about 700

‧Youyou Ux HC60, made by Nippon Oil Co., Ltd.

Polyethylene oxide hardened castor oil, weight average molecular weight: about 3,570

‧Vaseline, made by Japan Corning Co., Ltd.

Semi-solid from petroleum hydrocarbons

The IOB, melting point and water solubility of the above samples are shown in Table 2 below. The water solubility was measured according to the above method. However, in 100 g of demineralized water, 20.0 g was added, and the sample dissolved after 24 hours was evaluated as "20 g <", while in 100 g of the desalted water, 0.05 g was dissolved, but 1.00 g was not dissolved. The sample was evaluated to be 0.05 to 1.00 g. Further, regarding the melting point, "<45" means that the melting point is less than 45 °C.

The skin contact surface of the surface sheet of the above sanitary napkin is coated with the above blood modifying agent. For each blood modifying agent, if the blood modifying agent is liquid at room temperature, if the blood modifying agent is solid at room temperature, then heating to a melting point of +20 ° C, and then using a controlled slit HMA gun, After the respective blood modifying agents were micronized, the entire skin contact surface of the surface layer was applied to a basis weight of about 5 g/m ² .

Figure 14 shows a surface layer sheet containing three C2L oil fatty acids. An electron micrograph of the skin contact surface of the surface sheet in the physiological cotton (No. 2-5) of glyceride. As is apparent from Fig. 14, the tri-C2L oil fatty acid glyceride adhered to the surface of the fiber in the form of fine particles.

According to the above sequence, the rate of rewet and the rate of migration of the absorber were measured. The results are shown in Table 2 below.

〔experiment method〕

On the surface sheet containing each blood modifying agent, an acrylic plate (200 mm × 100 mm, 125 g, 40 mm × 10 mm hole in the center) was placed, and 37 ± 1 ° C horse EDTA blood was added from the above hole. (To prevent coagulation, add ethylenediaminetetraacetic acid (hereinafter referred to as "EDTA")) 3g using a pipette (first time), 1 minute, 37 ± 1 °C horse EDTA blood 3g self-acrylic The hole in the plate was again dripped with a pipette (second time).

Immediately after the second blood drop, the acrylic plate was taken out, and 10 pieces of filter paper (Advantech Toyo Co., Ltd. qualitative filter paper No. 2, 50 mm × 35 mm) were placed at the place where the blood was dropped, and the weight was placed from above to the pressure. It is 30 g/cm ² . After 1 minute, the filter paper was taken out, and the "return-in rate" was calculated in the following manner.

Infiltration rate (%) = 100 × (quality of filter paper after test - original filter paper quality) / 6

Further, unlike the evaluation of the rewet rate, after the second blood drop, the "absorbent migration speed" of the time when the blood moves from the surface sheet to the absorber is measured. The above-mentioned absorber migration speed is expressed from the surface sheet input After the blood, on the surface and inside of the surface sheet, the time until the red color of the blood is not seen.

The results of the rewet rate and the displacement speed of the absorber are shown in Table 2 below.

Next, the whiteness of the skin contact surface of the surface sheet after the test of the absorption speed of the absorbent body was visually evaluated based on the following criteria.

◎: There is almost no residue in the red blood, and there is no difference between the presence and absence of blood.

○: Although the blood is slightly red, it is not easy to distinguish between the presence and absence of blood.

△: Some red blood with blood can distinguish the presence of blood

×: Red red residue of blood

The results were combined as shown in Table 2 below.

When there is no blood modifying agent, the re-infiltration rate is 22.7%, and the migration speed of the absorbent body exceeds 60 seconds. The osmosis rate of glycerol and fatty acid triester is 7.0% or less, and the absorption speed of the absorbent body is 8 seconds. Hereinafter, it is known that the absorption performance is improved to a large extent. However, in the triester of glycerin and fatty acid, the absorption performance of NA50 having a melting point exceeding 45 ° C is not greatly improved.

Similarly, it is known that for a pH modifier of from about 0.00 to about 0.60 and a melting point of about 45 ° C or less and 100 g of water at 25 ° C, the absorption property can be greatly improved in a blood modifier having a water solubility of about 0.00 to about 0.05 g. The ground is improved.

Next, after the physiological cotton of No. 2-1 to 2-47 is worn by a plurality of volunteers, the physiological sanitary napkin containing the blood modifying agent in No. 2-1 to 2-32 is used. Even if the menstrual blood is absorbed, there is no sticky feeling on the surface layer, and the surface layer is refreshed.

Further, in the sanitary napkins of No. 2-1 to No. 2-32, particularly the physiological sanitary napkins containing the blood modifying agents of Nos. 2-1 to 11, 15 to 19 and 32, menstrual blood is obtained. The skin contact surface of the absorbed topsheet is not stained red by blood and is less irritating.

[Example 2]

Regarding the various blood types of animals, the rate of rewet is evaluated according to the above sequence. The blood used in the experiment is as follows.

[animal species]

(1) Human

(2) Horse

(3) sheep

[blood species]

‧Defibration: After taking blood, put it in a triangular beaker with glass beads for about 5 minutes.

‧EDTA blood: Add 12% EDTA‧2K physiological saline solution 0.5mL to venous blood 65mL

〔distinguish〕

Serum or plasma: clear liquid after centrifugation of each defibrinated blood or EDTA blood at room temperature for about 10 minutes at about 1900G

Blood cells: serum is removed from the blood, and the residue is washed twice with phosphate buffered physiological saline solution (PBS), and then the phosphate buffered physiological saline solution of the removed serum portion is added.

An absorbent article was produced in the same manner as in Example 1 except that the amount of the C2L oil fatty acid glyceride was applied to a basis weight of about 5 g/m ² , and the various blood contents were evaluated for the back bleed rate. The measurement of each blood was performed three times, and the average value was used.

The results are shown in Table 3 below.

The same results as in the case of horse EDTA blood obtained in Example 2 were also obtained in human and sheep blood. Also, the same tendency was observed for defibrinated blood and EDTA blood.

[Example 3]

[evaluation of blood retention]

The blood retention in the surface layer containing the blood modifying agent and the surface layer containing no blood modifying agent was evaluated.

〔experiment method〕

(1) Three C2L oil fatty acid glycerin on the skin contact surface of a surface sheet formed of a gas permeable non-woven fabric (composite fiber composed of polyester and polyethylene terephthalate, basis weight: 35 g/m ² ) The ester was micronized using a controlled slit HMA gun and applied to a basis weight of about 5 g/m ² . Further, for comparison, a person who did not apply tri C2L oil fatty acid glyceride was prepared. Next, both the surface sheet coated with the tri-C2L oil fatty acid glyceride and the uncoated surface sheet were cut into a size of 0.2 g, and the mass (a) of the cell filter + surface sheet was accurately measured.

(2) About 2 mL of horse EDTA blood was added from the skin contact surface side, and left to stand for 1 minute.

(3) The cell filter is placed in a centrifuge tube to stop the rotation and then remove the remaining horse EDTA blood.

(4) The cell filter + weight (b) containing the surface layer of horse EDTA blood was measured.

(5) The initial absorption amount (g) of 1 g of each surface sheet was calculated according to the following formula.

Initial absorption = [weight (b) - weight (a)] / 0.2

(6) The cell filter was again placed on a centrifuge tube, and centrifuged at about 1200 G for 1 minute at room temperature.

(7) The cell filter + weight (c) containing the surface layer of horse EDTA blood was measured.

(8) The amount of absorption (g) after the test of 1 g of each surface sheet was calculated according to the following formula.

Absorption after test = [weight (c) - weight (a)] / 0.2

(9) The blood retention rate (%) was calculated according to the following formula.

Blood retention rate (%) = 100 × absorption after test / initial absorption

Further, the measurement was carried out 3 times, and the average value thereof was used.

The results are shown in Table 8 below.

The surface layer containing the blood modifying agent has low blood retention property, and can quickly move to the absorber after absorbing blood.

[Example 4]

[viscosity of blood containing blood modifying agent]

The viscosity of the blood containing the blood modifying agent was measured using a Rheometric Expansion System ARES (Rheometric Scientific, Inc.). 2% by mass of Panaseto 810s was added to the horse's fiber, and the sample was gently stirred to carry a sample, and the sample was placed on a parallel plate having a diameter of 50 mm, and the pitch was set to 100 μm, and the viscosity was measured at 37 ± 0.5 °C. On the parallel plate, the average shear rate indicated by the machine was 10 s ^-1 although the sample was evenly sheared.

The viscosity of the horse-fiber fiber containing Panaseto 810s 2% by mass is 5.9 mPa ‧ s, on the other hand, the horse defibration without the blood modifying agent The viscosity of the blood is 50.4 mPa ‧ s. Therefore, when the horse-fiber blood containing Panaseto 810s 2% by mass was compared with the blood-free modifier, it was found to be reduced by about 90%. It is known that blood contains a component such as a blood cell and has a property of touch modification. However, the blood modifying agent disclosed in the present invention can lower the blood viscosity in a low viscosity region. By lowering the blood viscosity, the absorbed menstrual blood can be quickly transferred from the surface sheet to the absorbent body.

[Example 5]

[Micrograph of blood containing blood modifying agent]

The menstrual blood of the health volunteer was taken as a wrap film (trademark), and Panaseto 810s dispersed in 10 times by mass of phosphate buffered physiological saline was added to the fraction, and the concentration added to Panaseto 810s was 1% by mass. The menstrual blood was dripped on a glass slide, covered with a cover glass, and the state of the red blood cells was observed with an optical microscope. A microscope photograph of menstrual blood containing no blood modifying agent is shown in Fig. 15 (a), and a microscope photograph of menstrual blood containing Panaseto 810s is shown in Fig. 15 (b).

As is apparent from Fig. 15, in the menstrual blood containing no blood modifying agent, red blood cells form aggregates such as rouleau formation, but in menstrual blood containing Panaseto 810s, red blood cells are stably dispersed. Therefore, the blood modifying agent can function as a stable red blood cell in the blood.

[Example 6]

[surface tension of blood containing blood modifying agent]

Surface tension of blood containing blood modifying agent using Concord Interface The Drop Master500, a contact angle meter, was measured by a drop-and-drop method. The surface tension is added to the defibrinated blood of the sheep to add a certain amount of the blood modifying agent, and the vibration is fully measured.

The measurement was automatically performed by a machine, and the density γ was obtained by the following formula (refer to Fig. 16).

γ=g×ρ×(de) ² ×1/H

g: gravity constant

1/H: Correction by ds/de

ρ: density

De: maximum diameter

Ds: diameter by which the drop end is only raised

The density ρ is measured according to the "vibration test method and density ‧ mass ‧ capacity conversion table" of JIS K 2249-1995, and is measured at the temperature shown in the following Table 5.

The measurement was performed using DA-505 of Kyoto Electronics Industry Co., Ltd.

The results are shown in Table 5.

As is apparent from Table 5, the blood modifying agent has a water solubility of about 0.00 to about 0.05 g for 100 g of water at 25 ° C, and the solubility in water is extremely low, but the surface tension of blood is lowered. By lowering the surface tension of the blood, the absorbed blood does not remain between the fibers of the surface sheet, and is quickly moved to the absorbent body.

One or a combination of the embodiment and the modification may be plural. Modifications can also be combined with each other.

The above description is only an example, and the present invention is not limited to the above embodiments.

1‧‧‧Absorbables

2‧‧‧Skin sheet

3‧‧‧Back sheet

4‧‧‧Acceptor

5‧‧‧ side layer

6‧‧‧Wings

8‧‧‧ Pressing ditch

9‧‧‧ Sealing Department

10‧‧‧ Body Department

16‧‧‧Excretion junction area

18‧‧‧ Blood Modifier Coating Area

61‧‧‧ Pedestal

62‧‧‧ outer edge

Claims (14)

An absorbent article comprising a body portion and a pair of wing portions extending in a width direction from both side edges of the body portion, wherein the body portion has liquid permeability provided on the skin side An absorbent article of a non-woven surface sheet, a liquid-impermeable back sheet provided on the garment side, and a liquid-retaining absorbent body provided between the surface sheet and the back sheet, wherein the surface sheet is The excretory port engagement region that is connected to at least the wearer's excretory opening on the side of the skin is provided with a protrusion, and the surface layer sheet is such that at least the excretory port engagement region further includes a composition coating region to which the predetermined composition is applied. The absorbent article according to claim 1, wherein the protrusions extend in a predetermined direction and include protrusions and recesses which are arranged side by side in the direction of the predetermined direction. The absorbent article of claim 2, wherein the protrusion is formed by injecting a gas from a network of the surface sheet. The absorbent article of claim 3, wherein the fiber density at the central portion of the protrusion is lower than the fiber density of the side portion of the protrusion and/or the fiber density of the recess. The absorbent article of claim 2, wherein the protrusion is formed by bending a non-woven fabric of the surface sheet. The absorbent article according to any one of claims 3 to 5, wherein the concave portion of the surface layer sheet has an opening portion, and a fiber density of a side surface of the opening portion is higher than a fiber density at a central portion of the protrusion portion. An absorbent article having a long direction and a wide direction, including The main body portion and the pair of wing portions extending from the both side edges of the main body portion in the width direction, the main body portion being a surface sheet having a liquid permeable non-woven fabric provided on the skin side, and the liquid disposed on the garment side is impervious An absorbent article for a back sheet and a liquid-retaining absorbent body disposed between the surface sheet and the back sheet, characterized in that the excretion port of the at least one of the side surfaces of the skin is in contact with the excretory port From the surface sheet to the inside of the absorber, a compression portion formed by embossing, wherein the surface sheet has at least the excretion port engagement region having a composition application region to which a predetermined composition is applied. The absorbent article according to any one of claims 1 to 7, wherein the composition coating region is provided when the pair of wing portions are folded inward in the width direction, and is provided to be hidden by the pair of wing portions In the range of the width, the outer side edges of the pair of wing portions can be engaged with each other. The absorbent article according to any one of claims 1 to 8, wherein the wing portion has a protrusion on a side of the skin. The absorbent article according to any one of claims 1 to 9, wherein the composition is a blood having a melting point of 0.000 to 0.60, a melting point of 45 ° C or less, and a water solubility of 0.00 to 0.05 g for 100 g of water at 25 ° C. Quality agent. The absorbent article of claim 10, wherein the blood modifying agent is a group selected from the following (i) to (iii) and any combination thereof; (i) hydrocarbon, (ii) having (ii-1) a hydrocarbon portion and (ii-2) are inserted in the above hydrocarbon portion a compound of the same or a different group selected from the group consisting of a carbonyl group (-CO-) and an oxy group (-O-), and (iii) having a (iii-1) hydrocarbon moiety. And (iii-2) one or a plurality of identical or different groups selected from the group consisting of a carbonyl group (-CO-) and an oxy group (-O-) interposed between the CC single bonds of the above hydrocarbon moiety and (iii) a compound which substitutes one or more of the same or different groups of a carboxyl group (-COOH) and a hydroxyl group (-OH) in the hydrogen atom of the above hydrocarbon moiety; wherein the compound of (ii) or (iii) In the case where two or more oxy groups are inserted, each oxy group is not adjacent. The absorbent article of claim 10 or 11, wherein the blood modifying agent is a group selected from the group consisting of (i') to (iii') and any combination thereof; (i') hydrocarbon, (ii') a carbonyl bond (-CO-), an ester bond (-COO-), a carbonate bond (-) having a (ii'-1) hydrocarbon moiety and (ii'-2) inserted between the CC single bonds of the above hydrocarbon moiety One or a plurality of identical or differently bonded compounds of OCOO-) and an ether bond (-O-), and (iii') having (iii'-1) hydrocarbon moiety, (iii'-2) The group consisting of a carbonyl bond (-CO-), an ester bond (-COO-), a carbonate bond (-OCOO-), and an ether bond (-O-) interposed between the CC single bonds of the above hydrocarbon moiety One or more of the same or different linkages and one or more of the groups of (iii'-3) replacing the hydrogen atom of the above hydrocarbon moiety selected from the group consisting of a carboxyl group (-COOH) and a hydroxyl group (-OH) a compound of a hetero group; wherein two or more of the compounds of (ii') or (iii') are inserted When the same or different bonds are bonded, the bonds are not adjacent. The absorbent article according to any one of claims 10 to 12, wherein the blood modifying agent is a group selected from the following (A) to (F) and any combination thereof; (A) (A1) has a chain a compound having a hydrocarbon portion and 2 to 4 hydroxyl groups which replace the hydrogen atom of the above-mentioned chain hydrocarbon portion, and (A2) an ester having a chain hydrocarbon portion and a compound which substitutes one carboxyl group of a hydrogen atom of the above-mentioned chain hydrocarbon portion, B) (B1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups which replace the hydrogen atom of the above-mentioned chain hydrocarbon moiety, and (B2) 1 having a chain hydrocarbon moiety and a hydrogen atom replacing the above chain hydrocarbon moiety The ether of the hydroxy compound, (C) (C1) contains a chain hydrocarbon moiety and a carboxylic acid, a hydroxy acid, an alkoxy acid or a carbonyl acid of the 2 to 4 carboxyl groups which replace the hydrogen atom of the above-mentioned chain hydrocarbon moiety (C2) An ester having a chain hydrocarbon moiety and a compound constituting one hydroxyl group of a hydrogen atom of the above-mentioned chain hydrocarbon moiety, (D) having a chain hydrocarbon moiety and a CC single bond inserted in the chain hydrocarbon moiety selected from an ether (1) a compound bonded to a bond (-O-), a carbonyl bond (-CO-), an ester bond (-COO-), and a carbonate bond (-OCOO-), (E) polyoxy C ₂ ~C ₆ alkanediol or its alkyl group The ester is either an alkyl ether or a (F) chain hydrocarbon. The absorbent article according to any one of claims 10 to 13, wherein the blood modifying agent is an ester selected from the group consisting of (a ₁ ) chain hydrocarbon tetraol and at least one fatty acid, (a ₂ ) chain hydrocarbon triol An ester with at least one fatty acid, an ester of (a ₃ ) a chain hydrocarbon diol and at least one fatty acid, (b ₁ ) a chain hydrocarbon tetraol, and an ether of at least one aliphatic monohydric alcohol, (b ₂ ) An ether of a chain hydrocarbon triol and at least one aliphatic monohydric alcohol, (b ₃ ) a chain hydrocarbon diol and an ether of at least one aliphatic monohydric alcohol, (c ₁ ) a chain hydrocarbon having 4 carboxyl groups An ester of a tetracarboxylic acid, a hydroxy acid, an alkoxy acid or a carbonyl acid with at least one aliphatic monohydric alcohol, (c ₂ ) a chain hydrocarbon tricarboxylic acid having three carboxyl groups, a hydroxy acid, an alkoxy acid or An ester of a carbonyl acid with at least one aliphatic monohydric alcohol, (c ₃ ) a chain hydrocarbon dicarboxylic acid having two carboxyl groups, a hydroxy acid, an alkoxy acid or a carbonyl acid and at least one aliphatic monohydric alcohol Esters, (d ₁ ) aliphatic monohydric alcohols and ethers of aliphatic monohydric alcohols, (d ₂ ) dialkyl ketones, esters of (d ₃ ) fatty acids with aliphatic monohydric alcohols, (d ₄ ) dialkyl carbonate, (e ₁₎ polyoxy C ₂ ~ C ₆ alkylene glycol, (e ₂₎ polyoxy C ₂ ~ C ₆ alkyl with at least one aliphatic diol Acid esters, ethers (e ₃₎ polyoxy C ₂ ~ C ₆ alkylene glycol and at least one aliphatic monohydric alcohol, (e ₄₎ polyoxy C ₂ ~ C ₆ alkylene glycol and a chain hydrocarbon tetracarboxylic An acid, a chain hydrocarbon tricarboxylic acid or an ester of a chain hydrocarbon dicarboxylic acid, (e ₅ ) a polyoxy C ₂ -C ₆ alkanediol and a chain hydrocarbon tetraol, a chain hydrocarbon triol or a chain diol The ether, and (f1) chain alkane, and any combination thereof are grouped.